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ABSTRACT
The human placenta develops from highly proliferative and phenotypically plastic cells
called trophoblasts. Bi-potential trophoblast stem cells differentiate into the villous
pathway to form the syncytiotrophoblast layer and the extravillous trophoblast (EVT).
The HTR-8/SVneo cell line is widely used to study trophoblast biology. These cells
variably express villous-specific or EVT-specific genes depending on conditions. Such
phenotypic plasticity is indicative of a bi-potential cytotrophoblast progenitor.
Preliminary work has shown that similar to progenitors in situ, a subpopulation of HTR8/SVneo cells expresses α6β4 integrin. This α6β4high subset exhibits enhanced
clonogenicity and differentiation capacity. This cell line also expresses Nodal, a stem
cell-associated factor that sustains the pluripotency of embryonic stem cells and is reexpressed in certain cancers. I hypothesized that the α6β4high subset within HTR8/SVneo is enriched with bi-potential cytotrophoblast progenitor-like cells that are
maintained by Nodal signaling. Our results revealed that the α6β4high subset expresses
greater amounts of Nodal protein relative to the α6β4low subset. To investigate the role of
Nodal in regulating trophoblast progenitors, stable Nodal knock-down and overexpressing cells were analyzed. It was found that Nodal is required for clonogenicity,
maintenance of enhanced α6β4 expression and endovascular differentiation along the
EVT pathway. These results suggest that the α6β4high population may represent a villous
cytotrophoblast progenitor cell in which Nodal regulates clonogenicity and capacity for
differentiation along the EVT pathway.

Key Words: Placenta, Trophoblast, HTR-8/SVneo, BeWo, Nodal, Trophoblast
differentiation, Endothelial Tube-Formation, hCG.
iii	
  

	
  
ACKNOWLEDGEMENTS
I would like to thank my supervisors, Dr. Lynne-Marie Postovit and Dr. Peeyush
K. Lala, for accepting me into their lab family and helping me develop into a successful
young scientist.
I would also like to thank all the members of the Postovit and Lala laboratories,
for their friendship and guidance during my past two years here: Padmalaya Das, Daniela
Quail, Guihua Zhang, Michael Jewer, Scott Findlay, Krista Vincent, Leanna Dunn, Girish
Gannareddy, Mousumi Majumder, Mauricio Rodriguez Torres, and Xiping Xin.
I also thank my supervisory committee members: Dr. Alison Allan and Dr. Andy
Babwah for their support and input.
Lastly, I’d like to thank my friends and family, especially Alex Coe for cheering
me up when the going got tough, and my Mom, Dad, and sisters who are constant sources
of joy and inspiration. Thank you for your support and encouragement. I could not have
done this without you.

iv	
  

	
  
TABLE OF CONTENTS
CERTIFICATE	
  OF	
  EXAMINATION	
  ......................................................................................................	
  ii	
  
ABSTRACT	
  ..............................................................................................................................................	
  iii	
  
ACKNOWLEDGEMENTS	
  .......................................................................................................................	
  iv	
  
TABLE	
  OF	
  CONTENTS	
  ............................................................................................................................	
  v	
  
LIST	
  OF	
  FIGURES	
  ....................................................................................................................................	
  vi	
  
LIST	
  OF	
  TABLES	
  ..................................................................................................................................	
  viii	
  
LIST	
  OF	
  ABBREVIATIONS	
  ....................................................................................................................	
  ix	
  
Chapter	
  One:	
  Introduction	
  ..................................................................................................................	
  1	
  
1.1	
   The	
  Placenta	
  ....................................................................................................................................................	
  2	
  
1.1.1	
  Blastocyst	
  Implantation	
  ..............................................................................................................................	
  2	
  
1.1.2	
  Development	
  of	
  Villi	
  ......................................................................................................................................	
  4	
  
1.1.3	
  Trophoblast	
  Invasion	
  ....................................................................................................................................	
  4	
  
1.1.4	
  Spiral	
  Arterial	
  Remodeling	
  .........................................................................................................................	
  6	
  
1.1.5	
  Regulation	
  of	
  Trophoblast	
  Differentiation	
  ..........................................................................................	
  7	
  
1.1.5.1	
  Cytotrophoblast	
  –	
  Proliferation	
  .................................................................................................	
  7	
  
1.1.5.2	
  Syncytiotrophoblast	
  –	
  Fusion	
  ...................................................................................................	
  10	
  
1.1.5.3	
  EVT	
  –	
  Migration	
  &	
  Invasion	
  ......................................................................................................	
  11	
  
1.1.6	
  Models	
  of	
  Placental	
  Development	
  .........................................................................................................	
  13	
  
1.2	
  Nodal	
  ......................................................................................................................................................................	
  15	
  
1.2.1	
  The	
  Nodal	
  Signaling	
  Pathway	
  .................................................................................................................	
  16	
  
1.2.2	
  Regulation	
  of	
  Nodal	
  Signaling	
  ................................................................................................................	
  18	
  
1.2.3	
  Nodal	
  and	
  Development	
  ............................................................................................................................	
  20	
  
1.2.4	
  Nodal	
  and	
  Cancer	
  .........................................................................................................................................	
  22	
  
1.2.5	
  Nodal	
  and	
  Placentation	
  .............................................................................................................................	
  26	
  
1.3	
  Rationale	
  ..............................................................................................................................................................	
  30	
  
1.4	
  Hypothesis	
  ...........................................................................................................................................................	
  32	
  
Chapter	
  Two:	
  Materials	
  &	
  Methods	
  ..............................................................................................	
  33	
  
Chapter	
  Three:	
  Results	
  ......................................................................................................................	
  41	
  
Co-‐Authorship	
  Statement	
  .....................................................................................................................................	
  42	
  
Chapter	
  Four:	
  Discussion	
  .................................................................................................................	
  64	
  
4.1	
  HTR-‐8/SVneo	
  &	
  BeWo:	
  Models	
  for	
  Trophoblast	
  Self-‐Renewal	
  &	
  Differentiation	
  ................	
  66	
  
4.2	
  Nodal	
  Signaling	
  &	
  Cytotrophoblast	
  Progenitors	
  ................................................................................	
  68	
  
4.3	
  Nodal	
  &	
  Trophoblast	
  Self-‐Renewal/Proliferation	
  .............................................................................	
  71	
  
4.4	
  Nodal	
  &	
  Trophoblast	
  Differentiation	
  ......................................................................................................	
  74	
  
4.5	
  Experimental	
  Limitations	
  .............................................................................................................................	
  77	
  
4.6	
  Future	
  Directions	
  .............................................................................................................................................	
  78	
  
References:	
  ............................................................................................................................................	
  79	
  
Appendix:	
  Supplemental	
  Figures	
  ..................................................................................................	
  94	
  
Curriculum	
  Vitae	
  ...............................................................................................................................	
  101	
  
	
  

	
  

v	
  

	
  
LIST OF FIGURES
Figure 1. Human Blastocyst Implantation	
  ...........................................................................................	
  3	
  
Figure 2. The Chorionic Villi	
  ...................................................................................................................	
  5	
  
Figure 3. Regulation of Trophoblast Differentiation	
  .......................................................................	
  8	
  
Figure 4. The Nodal Signaling Pathway	
  ...........................................................................................	
  17	
  
Figure 5. Integrin α6β4high cells express higher levels of Nodal protein compared to
α6β4low cells.	
  ....................................................................................................................................	
  44	
  
Figure 6. Integrin α6β4high cells do not exhibit altered growth rate or proliferation relative
to α6β4low and unsorted controls.	
  ..............................................................................................	
  45	
  
Figure 7. Stable Nodal knock-down in HTR-8/SVneo trophoblast cells.	
  ..............................	
  47	
  
Figure 8. Nodal knock-down decreases expression of integrin α6β4.	
  ....................................	
  48	
  
Figure 9. Stable Nodal over-expression in BeWo choriocarcinoma cells.	
  ............................	
  49	
  
Figure 10. Nodal over-expression increases expression of integrin α6β4.	
  ...........................	
  50	
  
Figure 11. Nodal knock-down reduces HTR-8/SVneo clonogenicity.	
  ...................................	
  52	
  
Figure 12. Nodal over-expression increases BeWo clonogenicity.	
  ..........................................	
  53	
  
Figure 13. Nodal knock-down decreases HTR-8/SVneo growth rate but increases
proliferation.	
  .....................................................................................................................................	
  54	
  
Figure 14. Nodal over-expression does not affect BeWo growth or proliferation.	
  .............	
  55	
  
Figure 15. Nodal knock-down decreases the ratio of metabolically active to apoptotic
cells in HTR-8/SVneo.	
  ..................................................................................................................	
  57	
  
Figure 16. Nodal over-expression decreases the ratio of metabolically active cells to
apoptotic cells in BeWo.	
  ...............................................................................................................	
  58	
  
Figure 17. Nodal knock-down increases hCG mRNA but not secreted protein in HTR8/SVneo cells.	
  ...................................................................................................................................	
  59	
  
Figure 18. Nodal over-expression does not affect hCG expression in BeWo cells.	
  ...........	
  60	
  
Figure 19. Nodal is required for HTR-8/SVneo tube-formation and VE-Cadherin
expression.	
  .........................................................................................................................................	
  62	
  
Figure 20. Nodal over-expression increases BeWo tube-formation.	
  .......................................	
  63	
  
Figure A1. Analysis of α6β4 expression in HTR-8/SVneo cells.	
  ............................................	
  95	
  
Figure A2. Isolation of α6β4high and α6β4low subsets from HTR-8/SVneo.	
  .........................	
  96	
  
vi	
  

	
  
Figure A3. Characteriziation of α6β4high and α6β4low subsets from HTR-8/SVneo.	
  ........	
  97	
  
Figure A4. Loss of HLA-G expression in HTR-8/SVneo.	
  ..........................................................	
  98	
  
	
  

	
  

vii	
  

	
  
LIST OF TABLES
Table A1. Top 20 increased miRNA and corresponding decreased target genes in
α6β4high relative to α6β4low subset……………..……………………………… ………….………100
	
  
	
  

	
  

viii	
  

	
  
LIST OF ABBREVIATIONS
ActRIIB	
  

Activin	
  Receptor	
  IIB	
  

ALK	
  

Activin	
  Like	
  Kinase	
  

CSF-‐1	
  

Colony	
  Stimulating	
  Factor-‐1	
  

CT	
  

Cytotrophoblast	
  

BMP	
  

Bone	
  Morphogenic	
  Protein	
  

ECM	
  

Extracellular	
  Matrix	
  

EGF	
  

Epidermal	
  Growth	
  Factor	
  

EGFR	
  

EGF	
  Receptor	
  

EGF-‐CFC	
  

Epidermal	
  Growth	
  Factor-‐Cripto-‐1/FRL-‐1/Cryptic	
  

EVT	
  

Extravillous	
  Trophoblast	
  

FGF4	
  

Fibroblast	
  Growth	
  Factor-‐4	
  

hCG	
  

Human	
  Chorionic	
  Gonadotropin	
  

hESC	
  

Human	
  Embryonic	
  Stem	
  Cell	
  

HLA	
  

Human	
  Leukocyte	
  Antigen	
  

HTR-‐8/SVneo	
  

Human	
  Trophoblast-‐8	
  SV/neo	
  

IGF	
  

Insulin-‐like	
  Growth	
  Factor	
  

IGFBP-‐1	
  

IGF	
  Binding	
  Protein-‐1	
  

IGFR	
  

IGF	
  Receptor	
  

MMP	
  

Matrix	
  Metalloproteinase	
  

PAI	
  

Plasminogen	
  Activator	
  Inhibitor	
  

PGE2	
  

Prostaglandin	
  E2	
  

PI3K	
  

Phosphoinositide-‐3	
  Kinase	
  

ix	
  

	
  
PlGF	
  

Placenta	
  Growth	
  Factor	
  

shRNA	
  

Short	
  Hairpin	
  Ribonucleic	
  Acid	
  

SMAD	
  

Mothers	
  Against	
  DPP	
  Homolog	
  

SPC	
  

Subtilisin-‐like	
  Proprotein	
  Convertase	
  

ST	
  

Syncytiotrophoblast	
  

TGF-‐β

Transforming Growth Factor-beta

TIMP

Tissue Inhibitors of Metalloproteinase

TSC

Trophoblast Stem Cell

uPA

Urokinase Plasminogen Activator

VEGF

Vascular Endothelial Growth Factor

VEGFR

VEGF Receptor

x	
  

	
  

Chapter One: Introduction
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1.1 The Placenta
The placenta is an organ required by Eutherian mammals for the successful
development of the fetus during pregnancy (reviewed by (Herr et al., 2010)). It supports
the development of a small number of fetuses within the protective maternal organism
through the establishment of a close fetal-maternal exchange network. The placenta also
accomplishes a variety of metabolic, hormonal and immunological functions necessary
for successful pregnancy. The three main types of placentae, which are categorized
according to their degree of uterus invasion, are the noninvasive “epitheliochorial”
placenta, the moderately invasive “endotheliochorial” placenta, and the highly invasive
“haemochorial” placenta (Chakraborty et al., 2002). The human placenta is of the third
category and behaves as a highly invasive tumour-like organ, which invades the maternal
uterine endometrium and vasculature, establishing vital fetal-maternal exchange (Lala &
Hamilton, 1996).
1.1.1 Blastocyst Implantation
The human placenta develops from highly proliferative and phenotypically plastic
cells called trophoblasts, which are derived from the trophectoderm of the preimplantation blastocyst (Lala & Hamilton, 1996). These trophoblast cells are
mononucleated and form a single layer that surrounds the inner cell mass and blastoceole
of the blastocyst (Huppertz, 2008). The trophoblasts adjacent to the inner cell mass,
known as polar trophoblasts, induce implantation by attaching to the uterine epithelium
and penetrating the basement membrane and underlying connective tissue (Lala &
Graham, 1990) (Figure 1).
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Figure 1. Human Blastocyst Implantation
Blastocyst implantation involves a number of steps: Transport – the blastocyst enters the
uterine cavity (A). Adhesion – The blastocyst adheres to the endometrial epithelium (B).
Invasion & Syncytialization – The polar trophoblasts penetrate the uterine epithelium and
basement membrane. Ten days post-fertilization, the invading trophoblasts fuse to form
the multinucleated syncytiotrophoblast, which invades the endometrium (C). Villous
formation – Fluid-filled spaces form within the syncytiotrophoblast and coalesce to form
lacunae which eventually develop into the intervillous space. The chorionic villi develop
from the syncytiotrophoblast between the large lacunae. The former trophectodermal
cells become the cytotrophoblast stem cells which maintain syncytiotrophoblast turnover
(D). Adapted from Moore and Persaud, 1998.
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1.1.2 Development of Villi
Approximately ten days after fertilization the invading polar trophoblasts fuse to form
multinucleated syncytiotrophoblasts (ST) (Anin et al., 2004; Jones & Fox, 1991). Fluidfilled spaces develop within the syncytiotrophoblast, forming lacunae. These lacunae
coalesce to form the intervillous spaces, while the syncytiotrophoblast develop into the
chorionic villi. Around weeks 10-12 of pregnancy, the intervillous spaces become filled
with maternal blood from ruptured endometrial capillaries. The maternal blood bathes
two types of chorionic villi: floating villi, which aid in the exchange of maternal and fetal
circulations, and anchoring villi, which contain migratory and invasive cytotrophoblasts
and anchor the placenta to the uterus (Bischof & Irminger-Finger, 2005) (Figure 2).
1.1.3 Trophoblast Invasion
Each villus is comprised of two layers of trophoblasts. The outer non-proliferative,
multinucleated syncytiotrophoblast layer is in direct contact with maternal blood and
mediates the exchange of gas, nutrients, and waste between the maternal and fetal
circulations (Lunghi et al., 2007; Yamamoto-Tabata et al., 2004). The
syncytiotrophoblast is also the site of hormone production, including progesterone and
human chorionic gonadotropin (hCG), which maintains the hormonal activity of the
corpus luteum during pregnancy. The inner layer of proliferative, mononucleated
trophoblasts called, cytotrophoblasts, acts as a source of stem cells for the dynamic
syncytiotrophoblast within the floating villi, and the invasive and migratory
cytotrophoblast within the anchoring villi (Huppertz, 2008). Cytotrophoblast cells within
the floating villi proliferate and daughter cells differentiate and fuse with the overlying
syncytiotrophoblast layer to maintain the multinucleated mass.
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Figure 2. The Chorionic Villi
By weeks 10-12 of pregnancy, the intervillous space has developed and is filled with
blood from maternal spiral arteries. The blood bathes the chorionic villi, both floating and
anchoring. Each villi is lined by two layers of trophoblast, the outer non-proliferative,
multinucleated syncytiotrophoblast (ST) and the inner layer of polarized, mononucleated,
proliferative cytotrophoblasts (CT). A subpopulation of cytotrophoblast rapidly
proliferate, forming a cell column at the tips of anchoring villi and invade the
decidualized endometrium as extravillous trophoblast (EVT). The EVT cells differentiate
into three populations: (1) Interstitial EVTs which invade as far as the inner third of the
myometrium and eventually differentiate into giant multinuclear cells, (2) Endovascular
EVTs which surround and remodel the maternal spiral arteries to allow for ample blood
flow during the second and third trimesters of pregnancy, and (3) Cytotrophoblastic shell,
a cell layer separating the decidua from the sinusoids. Adapted from Graham & Lala,
1992.
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A subpopulation of cytotrophoblast in anchoring villi rapidly proliferate, form a cell
column, and subsequently differentiate and migrate into the decidualized endometrium as
extravillous trophoblast (EVT) cells. The proliferative capacity of cells within the column
is gradually reduced as they migrate and invade the decidua. Three populations of EVT
cells form: (a) interstitial EVTs which invade up to the inner third of the myometrium
and fuse into giant multinuclear cells; (b) endovascular EVTs which target and invade
maternal spiral arteries, replacing the endothelial cells lining the vessels; and (c)
cytotrophoblastic shell, a cell layer that separates the decidua from the sinusoids (Aldo et
al., 2007; Espinoza et al., 2006; Pijnenborg et al., 2006; Huppertz, 2008).
1.1.4 Spiral Arterial Remodeling
Extensive blood flow into the intervillous space is required to support the increasing
needs of the growing fetus during the second and third trimesters of pregnancy
(Charnock-Jones et al., 2004; Torry et al., 2007). This is accomplished by the remodeling
of the maternal spiral arteries which leads to the disappearance of the smooth muscle
layer from the vessel wall and the replacement of endothelial cells by endovascular
EVTs. These trophoblast subsequently deposit a fibrinoid matrix (comprised of
fibronectin, collagen type IV and laminin) along the vessel wall, substituting the normal
elastic and collagenous extracellular matrix (Frank et al., 1994; Whitley & Cartwright,
2010), thereby transforming these high-resistance, low-flow muscular arteries into large
flaccid vessels lacking vasomotor control (Burton et al., 2009). The resulting vessels
experience a 10-fold increase in diameter, which increases the total blood volume
delivered to the intervillous space by 3 to 4-fold while reducing pressure (Kliman, 2000;
Thaler et al., 1990; Whitley & Cartwright, 2009).
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1.1.5 Regulation of Trophoblast Differentiation
Distinct trophoblast cell types develop during placental development, namely the
syncytiotrophoblast and EVT, which contribute to fetal-maternal exchange and invasion
of the uterine endometrium and its vasculature, respectively (Lunghi et al., 2007). Each
lineage is derived from villous cytotrophoblasts, the stem cell population in the placenta.
Cytotrophoblasts are polarized, mononucleated and rapidly proliferating epithelial cells
that line the basement membrane of the chorionic villi. Their proliferation and
differentiation are strictly regulated by a variety of endogenous and exogenous molecules
such as transcription factors, adhesion molecules, hormones, growth factors, cytokines
and oxygen levels (Figure 3).
1.1.5.1 Cytotrophoblast – Proliferation
The cytotrophoblast stem cells maintain syncytiotrophoblast and EVT turnover,
however, several transcription factors function to inhibit differentiation in favor of
cytotrophoblast proliferation. The factors Hash-2 and Id-2 maintain cytotrophoblast
proliferation, and are downregulated upon differentiation (Janatpour et al., 1999;
Janatpour et al. 2000). A study of cytotrophoblasts transduced to constitutively express
Id-2 found that these cells remained undifferentiated, as cyclin B expression was
maintained and α1 integrin expression was suppressed (Janatpour et al., 2000). More
recently, Hemberger and colleagues (2010) identified ELF5 as an important transcription
factor for the maintenance of human cytotrophoblast stem cells. ELF5 is highly expressed
in first trimester villous cytotrophoblast, but not in the more differentiated
syncytiotrophoblast or EVT cells, and is strongly down-regulated towards the end of
gestation. They established that ELF5, along with CDX2 and EOMES, forms a mutually

7	
  

	
  

	
  
Figure 3. Regulation of Trophoblast Differentiation
Schematic diagram of cytotrophoblast (CT) differentiation to syncytiotrophoblast (ST) or
extravillous trophoblast (EVT), together with key factors involved in the regulation of
these events. The box on the left lists factors stimulating CT proliferation, thus inhibiting
differentiation. Boxes on the right list factors stimulating ST or EVT differentiation.
Adapted from Lunghi et al., 2007.
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interacting trophoblast transcriptional network, and that ELF5+/CDX2+ cytotrophoblasts
(which persist until 13 weeks of gestation) may represent a highly proliferating, selfrenewing trophoblast stem cell population. Additionally, they have shown that in contrast
to placental trophoblasts, ELF5 is hypermethylated and chiefly repressed in hESC as well
as hESC derived trophoblast cell lines, outlining the importance of epigenetic regulation
in trophoblast fate determination.
Several studies have established the critical role of oxygen tension in the control
of trophoblast differentiation. Blastocyst implantation, placentation, and early embryonic
development occur in a relatively low oxygen environment (Lash et al., 2002). Low O2
levels stimulate cytotrophoblast proliferation and inhibit differentiation, while high O2
levels inhibit proliferation and stimulate differentiation (Genbacev et al. 1997; Caniggia
et al. 2000). Hypoxia stimulates hypoxia inducible factor-1 (HIF-1) and Hash-2, which
maintains cytotrophoblast proliferation and inhibits differentiation, respectively
(Janatpour et al., 1999; Janatpour et al., 2000, Baczyk et al., 2004). Cytotrophoblasts also
express TGF-β3, an inhibitor of trophoblast differentiation that impedes the acquisition of
the invasive phenotype (Genbacev et al., 1996; Caniggia et al., 2000). In accordance with
the above findings, it has been shown that invading cytotrophoblasts downregulate the
expression of both HIF-1 and TGF-β3, with HIF-1 acting upstream of TGF-β3 (Caniggia
et al., 1999; Caniggia et al., 2000).
A variety of growth factors produced at the fetal-maternal interface were shown to
promote cytotrophoblast proliferation in both autocrine (trophoblast derived) and
paracrine (decidua-derived) manners. They include EGF-R ligands such as EGF, TGF-α
and amphiregulin, VEGF, PlGF, CSF-1 (Chakraborty et al., 2002; Lala & Chakraborty,
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2003). On the other hand, the negative regulation of proliferation is primarily paracrine,
mediated by decidua-derived factors such as TGF-β and a TGF-β-binding leucine-rich
proteoglycan, decorin (Graham et al., 1992; Lysiak et al., 1995; Xu et al., 2002).
1.1.5.2 Syncytiotrophoblast – Fusion
Trophoblast differentiation into the peri-implantation invasive syncytiotrophoblast
is initiated upon attachment to the endometrial epithelium, where decidua-derived factors
stimulate fusion and the acquisition of an invasive phenotype. Syncytial fusion occurs
through the retroviral envelope protein, Syncytin. The transcription factor, glial cell
missing 1 (GCM1) along with AP-2 and Sp transcription factor families are upregulated
in pre-fusing cytotrophoblasts and induce expression of Syncytin (Yu et al., 2002; Frendo
et al., 2003; Baczyk et al., 2004). It is well established that syncytialization can be
initiated by certain cytokines, such as epidermal growth factor (EGF) which is expressed
by both decidual and trophoblastic cells (Hofmann et al., 1991; Dakour, et al., 1999) and
has been shown to stimulate the production of hormones, including human placental
lactogen (hPL) and hCG (Maruo et al., 1995). hCG, itself regulates several processes
during pregnancy, including promotion of syncytiotrophoblast generation through
activation of the cAMP pathway (Licht et al., 2001; Yang, Lei, & Rao, 2003). Forskolin
directly activates adenlyate cyclase, thereby increasing cAMP, and is commonly used to
induce trophoblast fusion (Wice et al., 1990; Drewlo et al., 2008). Conversely, TGF-β1
has been shown to inhibit the formation of syncytiotrophoblast (Morrish, Bhardwaj, &
Paras, 1991). TGF-β was found to be elevated in plasma of preeclamptic mothers,
suggesting it may play a role in the impaired implantation associated with this disease
(Caniggia et al., 2000). Lastly, physiological factors are also important regulators of
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trophoblast differentiation: For example rising oxygen levels promote syncytial fusion
(Jiang et al., 2005).
1.1.5.3 EVT – Migration & Invasion
Uterine invasion by trophoblast cells is critical for successful pregnancy, and is
thus stringently regulated by a network of factors during gestation (Lala & Hamilton,
1996; Caniggia et al., 2000a; Chakraborty et al., 2002; Anin et al., 2004; Knofler, 2009).
While a multiplicity of factors, both autocrine and paracrine, promote trophoblast
migration and invasion, only a few molecules produced by the decidua or the
syncytiotrophoblast negatively regulate these functions (Lala & Chakraborty, 2003). For
example, IGFII, a trophoblast derived factor stimulates trophoblast migration by binding
to IGFRII (McKinnon et al., 2001). Similarly, trophoblast-derived uPA promotes
trophoblast migration as well as invasiveness. The migration-promoting action is due to
binding of the non-catalytic amino-terminal domain to high affinity uPA receptors
expressed by the EVT at the invasive front in a polarized manner (Liu et al., 2003),
whereas its catalytic domain promotes matrix degradation by plasmin-induced activation
of the MMPs (Lala & Chakraborty, 2003). Endothelin-1 produced by trophoblast and the
decidua promotes EVT migration by elevation of intracellular Ca2+ (Chakraborty et al.,
2003). A variety of decidua-derived factors also stimulate EVT motility. For example,
IGFBP-1 which mediates pro-migratory action by binding to the α5β1 integrin via its
RGD domain (Gleeson et al., 2001). Activin A is a pro-migratory factor abundantly
secreted by decidual cells (Jones et al., 2002). Activin A has been shown to upregulate
MMP-2 expression in cytotrophoblast cells, enhancing their outgrowth from villous cell
columns (Caniggia et al., 1997). Decidua-derived PGE2 promotes trophoblast migration

11	
  

	
  
via signaling through the prostaglandin receptor, EP1 and elevation of intracellular
calcium (Nicola et al., 2005) and EP2/EP4 by regulating Rho kinases and MAPK (Nicola
et al., 2007; Nicola et al., 2008).
Factors negatively regulating EVT migration and invasiveness are primarily
paracrine in origin. For example, TGF-β, produced by the syncytiotrophoblast and the
decidua, is a potent inhibitor of EVT migration and invasion (Graham & Lala, 1992). The
anti-invasive function is mediated by an upregulation of the endogenous tissue inhibitor
of MMPs (TIMP)-1 (Graham & Lala, 1991; Graham et al., 1992) and downregulation of
uPA (Graham, 1997). The anti-migratory function is due to an upregulation if integrins
making the cells more adhesive (Irving & Lala, 1995). It is important to note that the
inhibitory effects of TGF-β are lost in choriocarcinoma cells (eg. JAR and JEG-3 cell
lines); this may be partially attributed to the downregulation of Smad-3, a downstream
TGF-β signaling molecule (Xu et al., 2003). TNF-α produced by decidual macrophages
negatively regulates trophoblast invasiveness via an induction of nitric oxide (Cartwright
et al., 1999). Decorin, a decidua-derived proteoglycan, negatively regulates trophoblast
migratory function by binding to multiple tyrosine kinase receptors, in particular
VEGFR2 (Iacob et al., 2008). The VEGFR2 binding domain of decorin has recently been
mapped (Khan et al., 2011).
Integrins also play a role during EVT differentiation (Bischof et al., 1990).
Integrins are both receptors and adhesion molecules that bind specific extracellular
matrix (ECM) proteins and regulate adhesion, migration, invasion, cytoskeleton
reorganization and cellular signaling (Albelda & Buck, 1990). Cytotrophoblasts initially
express integrin α6β4, a laminin-5 receptor that maintains their adherence to the villous
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basement membrane (Korhonen et al. 1991; Damsky et al. 1994; Zhou et al., 1997). As
these cytotrophoblast migrate off the basement membrane and differentiate into EVTs
along the invasive pathway, they down regulate integrin α6β4 and up-regulate α1β1 and
α5β1 integrins, a laminin-2 and fibronectin receptor, respectively to promote
invasiveness by binding to the specific laminins and fibronectins abundantly expressed in
the decidua (Irving et al., 1995; Irving & Lala, 1995; Church et al., 1996). α5β1 also
functions as a migration promoting receptor for decidua-derived IGFBP-1 (Gleeson et al.,
2001).
Additionally, studies have revealed an epithelial-to-endothelial transition essential
for placental development and the remodeling of maternal uterine vasculature. For
example, cytotrophoblasts in the chorionic villi initially express the adherins junction
protein, E-Cadherin, a marker of polarized epithelium. Upon migration and
differentiation, however, these cells down regulate E-Cadherin and up-regulate VECadherin, an adhesion marker characteristic of endothelial cells (Zhou et al., 1997).
1.1.6 Models of Placental Development
Trophoblast cell culture models have provided significant insight into placental
development, particularly so for human studies, where in vivo experimentation is not
feasible. Until recently, the lack of human trophoblast stem and progenitor cell lines has
significantly deterred our understanding of the mechanisms regulating trophoblast
differentiation and how these mechanisms become unraveled in placental disorders.
Previous studies have employed BMP4 treated hESC (Xu et al., 2002a; Das et al., 2007)
primary CTs (Kliman et al., 1986; Fisher et al., 1989), chorionic villous explants
(Genbacev et al., 1993), virally transformed trophoblast cell lines (Chou et al., 1978), and
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choriocarcinoma cell lines (Pattillo et al., 1968). However, there are many inherent issues
with the models. For example, hESC derived trophoblast models may not accurately
represent true trophoblast cells, as they may not fully acquire the lineage-specific
epigenetic signature (Hemberger et al., 2010); use of short-term primary cultures prohibit
studies involving genetic manipulation that require long-term culture; primary cultures
are often heterogeneous, complicating the identification of cells responsible for specific
effects; and choriocarcinoma cells often behave differently from normal trophoblast due
to their malignant phenotype.
Fisher and colleagues recently isolated a trophoblast progenitor cell line from the
human chorion, offering a promising model for the study of trophoblast differentiation
(Genbacev et al., 2011). Immunolocalization of pluripotency factors (Oct4) and
trophoblast markers (cytokeratin 7, GCM1, Eomes, and Syncytin) in early gestation
placenta identified the chorion as a putative source for trophoblast progenitors. These
cells were isolated by enzymatic digestion and maintained in the presence of FGF2
(required for mouse stem cell self-renewal) and the ALK4/5/7 small molecule inhibitor,
SB431542 (thought to inhibit pluripotency and trigger emergence of trophoblast
progenitors) at 20% oxygen. The resulting colonies were dissociated and grown as
monolayers and were found to express GATA3/4, CK7, Eomes, geminin, GCM1,
neonatal FCγ receptor, and integrin α6. They were able to successfully induce
differentiation with FGF4 and EGF on Matrigel, which resulted in a mixed population of
mononuclear and multinuclear cells that expressed CK7, geminin, GCM1, Eomes, HLAG, hPL, hCG, and Syncytin. These cells also exhibited increased invasion and the
associated integrin switching from α6 to α1 as observed in invasive cytotrophoblast cells
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in situ. Two human trophoblast progenitor cell lines have been generated thus far and
continuously cultured for up to 25 passages without differentiation, promising invaluable
insight into the mechanisms involved in trophoblast differentiation and placental
development.
The immortalized human trophoblast cell line, HTR-8/SVneo, produced by
introducing the gene encoding the simian virus (SV) 40 large T antigen into a human first
trimester primary EVT cell line, HTR-8 (Graham et al., 1993), is widely used to study
trophoblast biology. This cell line has been shown to be morphologically similar to its
parental cell line and to express many of the markers of highly migratory EVT cells in
situ, including cytokeratin 7, 8 and 18, placental type alkaline phosphatase, high affinity
urokinase-type plasminogen activator (uPA) receptor, and integrins α1, α3, α5, αv, β1
and the vitronectin receptor αvβ3/β5 (Irving et al., 1995; Irving & Lala, 1995; McKinnon
et al., 2001; Gleeson et al., 2001; Nicola et al., 2005). These cells have also been
observed to variably express villous-specific genes such as β-hCG and EVT-specific
genes such as HLA-G depending on conditions (Zdravkovic et al., 1999). Such
phenotypic plasticity is suggestive of a bi-potential cytotrophoblast progenitor
population. Interestingly, this cell line also expresses the stem cell-associated factor,
Nodal (Munir et al., 2004).
1.2 Nodal
Nodal is an embryonic morphogen that plays crucial roles during embryogenesis
(Schier, 2003; Hendrix et al., 2007; Strizzi et al., 2008). Nodal is also a stem cell
associated factor that maintains the pluripotency of embryonic stem cells, and is downregulated with differentiation (Schier, 2003; Hendrix et al., 2007). Nodal is a member of
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the TGF-β superfamily. This family encompasses 40 structurally related cell growth and
differentiation factors, many of which are abundantly and dynamically expressed in the
endometrium and placenta throughout gestation, including TGF-β and Activin. Recently,
Nodal and its extracellular inhibitor, Lefty, have also been implicated in the regulation of
placentation (Lowe et al., 2001; Ma et al., 2001; Guzman-Ayala et al., 2004; Munir et al.,
2004; Tang et al., 2005; Nadeem et al., 2011). However, the precise role of Nodal
signaling in the regulation of trophoblast differentiation remains unclear and is the focus
of this study.
1.2.1 The Nodal Signaling Pathway
Nodal signals extracellularly by binding the heterodimeric complex between type
I (ALK4/7) and type II (ActRIIB) activin-like kinase receptors (Figure 4). ActRIIB
activates ALK4/7 via phosphorylation, which then phosphorylates and activates
cytoplasmic Smad2/3. Phosphorylated Smad2/3 associates with Smad4 and translocates
to the nucleus where it associates with various transcription factors, including forkhead
box HI (FoxH1) and Mixer, and binds to the promoters of numerous target genes to
regulate gene expression. The epidermal growth factor-cripto FRL1 cryptic (EGF-CFC)
family co-receptor, Cripto, associates with Nodal and the ALK4 receptor to aid binding
and increase Nodal signaling (Yeo & Whitman, 2001; Reissmann et al., 2001; Bianco et
al., 2002). Cripto has also been demonstrated to interact with ALK7 (Reissman et al.,
2001) and therefore assists Nodal signaling through both ALK4 and ALK7 receptors.
However, while Nodal requires Cripto to bind ALK4, Nodal can bind directly to ALK7
without the assistance of Cripto (Reissman et al., 2001). It was recently discovered that
Cripto interacts with the Nodal pro-domain along with the convertases, Furin and Pace4,
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Figure 4. The Nodal Signaling Pathway
Nodal is initially secreted as a proprotein and must be activated via cleavage by the
convertases Pace4 and Furin. Nodal signaling is propagated through the type I and type II
activin-like kinase receptors, ALK4/7 and ActRIIB, as well as the coreceptor, Cripto.
Nodal signaling is transmitted intracellularly via the phosphorylation of Smad2/3 and its
association with Smad4 and transcription factors. The extracellular molecule, Lefty
inhibits Nodal signaling. Adapted from Hendrix et al. 2007.
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suggesting that it forms a Nodal-processing complex at the plasma membrane, providing
yet another mechanisms by which Cripto enhances Nodal signaling (Blanchet et al.,
2008).
The type I ALK receptors are not only critical for signal propagation but also
signal specificity. For example, while Nodal has been shown to signal through both
ALK4 and ALK7, the downstream signaling from these receptors produce dramatically
different biological responses. Activin signaling through ALK4 promotes cytotrophoblast
outgrowth and MMP-2 secretion (Caniggia et al., 1997). Conversely, Nodal signaling
through ALK7 inhibits EVT invasion (Nadeem et al., 2011). Moreover, multiple ligands
can signal through the same ALK receptor, for example both Nodal and Activin signal
through ALK4 (Massague et al., 1998). In this case, presence of the co-receptor Cripto
determines which ligand signals through the receptor (Yeo & Whitman, 2001): The
presence of Cripto enhances Nodal signaling, while blocking Activin signaling (Yeo &
Whitman, 2011; Yan et al., 2002).
1.2.2 Regulation of Nodal Signaling
Nodal signaling is regulated at multiple steps that include post-translational
modifications, proteolytic cleavage, extracellular inhibitors, and epigenetic mechanisms.
Nodal is initially secreted as a pro-protein and contains two post-translational
modification sites for N-linked glycosylation within the pro-domain region. To become
activated, Nodal must be cleaved by the subtilisin-like proprotein convertase (Spc)
enzymes, Spc1 (Furin) and Spc4 (PACE4) (Beck et al., 2002). Studies in zebrafish
revealed that the N-linked glycosylations stabilize the pro-domain and inhibit cleavage
(Le Good, et al., 2005). Once cleaved, protein stability is compromised, resulting in a
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reduced signaling range (Blanchet et al., 2008; Constam, et al., 2009). Therefore,
cleavage promotes autocrine signaling, while N-linked glycosylation promotes paracrine
signaling.
The Nodal signaling pathway is also self-regulated, including the up-regulation of
its own expression in a positive feedback loop as well as the up-regulation of its
endogenous inhibitors, Lefty. Lefty is another member the TGF-β superfamily and exists
as two isoforms, Lefty1 and Lefty2. Lefty1/2 inhibits Nodal signaling by direct
interaction with Nodal or Cripto in the cellular microenvironment or at the cell surface
(Schier, 2003). Cerberus is another antagonist of Nodal signaling. It is a member of the
DAN family of proteins that contain cysteine knots found in members of the TGF-β
superfamily. Cerberus blocks extracellular Nodal signaling through direct ligand binding.
Lastly, Tomoregulin-1 is a transmembrane protein that inhibits Nodal signaling through
its association with Cripto (Cheng et al., 2003).
Nodal transcription is also thought to be regulated by epigenetic mechanisms. The
Nodal gene contains a CpG island near its transcription start site, and studies in
melanoma cells have correlated levels of methylation of this region with Nodal
expression levels (Postovit et al., 2007). MicroRNA may also play a role in Nodal
regulation. For example, miR-430 has been shown to block translation of the zebrafish
Nodal equivalent, squint (Choi et al., 2007). It was recently observed that miR-218
expression is decreased in preeclamptic placenta compared to their gestational controls
(Zhu et al., 2009) and two potential target sites were identified in the 3’UTR of Nodal
(Brkic et al., 2012). These findings are supported by the report that Nodal inhibits
trophoblast migration and invasion and is overexpressed in preeclamptic placenta,
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suggesting that decreased miR-218 may lead to enhanced Nodal expression and
preeclampsia, and may thereby prove to be a promising target for treatment (Nadeem et
al., 2011).
1.2.3 Nodal and Development
Nodal was discovered through a retroviral induced mutation in the mouse called
413.d. Embryos homozygous for the mutation exhibited dramatic tissue malformations by
7.5 days of development and were embryonic lethal (Conlon et al., 1991). Eventually, the
mutation was mapped to a novel TGF-β superfamily growth factor called Nodal (Zhou et
al., 1993). Nodal has since been shown to be a critical regulator of embryonic
development; primarily in the establishment of anterior-posterior axis patterning and leftright asymmetry (Schier, 2003).
Nodal is initially expressed in the mouse epiblast shortly after implantation, and is
maintained through a positive feed-back loop (Ang & Constam, 2004). Nodal is
activated by convertases expressed in the adjacent extraembryonic ectoderm, which leads
to the induction of Lefty1 in the distal visceral endoderm, which eventually develops into
the anterior visceral endoderm (Schier, 2003). The restriction of Nodal signaling to the
proximal posterior region of the epiblast, by Lefty1 in the anterior visceral endoderm, is
crucial for anterior visceral endoderm displacement and positioning of the anteriorposterior axis (Zhou et al., 1993; Smith et al., 1995; Schier, 2003; Shiratori & Hamada,
2006; Schier, 2009). Following gastrulation, Nodal becomes restricted to the node in the
anterior primitive streak, hence the designation “Nodal” (Schier, 2003). The node is
where left-right axis formation occurs as Lefty1 restricts Nodal signaling to the left side
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of the embryo, where it facilitates mesoderm formation until it is downregulated and lost
at approximately 8 dpc (Collignon et al., 1996).
It has recently been shown that Nodal also regulates epigenetic phenomenon to
control stem cell differentiation (Dahle et al., 2010; Xi et al., 2011). Embryonic
development is regulated by both intercellular signaling and epigenetic mechanisms to
establish lineage specific patterns of gene expression. Histone acetylation and
methylation alter chromatin structure and therefore the accessibility of DNA (reviewed in
Dahle et al., 2010). Smad complexes can bind DNA and recruit histone acetyltransferases
to stimulate transcription, or histone deacetyltransferases to inhibit transcription
(Massague et al., 2005). Alternatively, these histone marks can also serve as binding sites
for transcriptional regulators, for example, trimethylation of Lys27 of Histone H3
(H3K27me3) acts as a binding site for Polycomb repressive complex 1, which inhibits
gene expression (Schuettengruber & Cavalli, 2009). Dahle and colleagues (2010)
demonstrated that the Nodal signaling complex, Smad2/3, binds the histone demethylase,
Jmjd3, and recruits it to the histone mark to counter inhibition by Polycomb and enable
transcription of downstream target genes. Epigenetic regulation enables the maintenance
of genomic programs that may be stably maintained across cell generations, but are also
able to respond to environmental cues (Mohn & Schubeler, 2009). For example, while
homeostasis genes generally have an active chromatin state, it has recently been observed
that master regulators of differentiation are transcriptionally silenced, but are poised for
activation by specific developmental signals (Young, 2011). Xi et al. (2011) have shown
that Nodal utilizes the poised histone mark H3K9me3 to trigger differentiation of
embryonic stem cells. Nodal signaling yields a TRIM33-Smad2/3 complex that binds
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H3K9me3 on the promoters of Gsc and Mixl1 (mesendoderm regulators), displacing
chromatin-compacting factor HP1γ, which exposes Nodal response elements (also known
as Activin Response Elements, ARE) and enables Smad4-Smad2/3 binding for Pol II
recruitment and differentiation.
Nodal signaling has also been implicated in the maintenance of human embryonic
stem cell (hESC) pluripotency (Vallier et al., 2004; James et al., 2005). It has been
shown that Nodal induces activation of Nanog transcription through Smad2/3; while
Nanog in turn interacts with Smad2/3 to inhibit the transcriptional activity of the Nodal
signaling pathway, and thereby prevent endoderm differentiation (Vallier et al., 2009).
Furthermore, Nodal/Activin inhibition in hESC through the receptor inhibitor, SB431542,
was found to induce neuroectoderm formation (Smith et al., 2008; Vallier et al., 2009;
Patani et al., 2009). Taken together, these studies indicate a role for Nodal in maintaining
hESC pluripotency by inhibiting neuroectoderm and mesendoderm differentiation.
Additionally, it has recently been suggested that Nodal also maintains the pluripotent
phenotype of cancer cells.
1.2.4 Nodal and Cancer
Nodal signaling has been implicated in several cancer types, including testicular,
prostate, liver, endometrial, ovarian, melanoma, breast, glioma, and pancreatic
(Lawrence, 2010; Adkins et al., 2003; Cavallari et al., 2012; Papageorgiou et al., 2009;
Xu et al., 2004; Topczewska et al., 2006; Strizzi et al., 2008; Lee et al., 2010; Lonardo et
al., 2011). It is thought that, similar to its effect on hESC, Nodal maintains an
undifferentiated, pluripotent phenotype in cancer cells, increasing aggressiveness and
tumourigenicity (Topczewska et al., 2006; Postovit et al., 2006; Kelusa et al., 2006;
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Postovit et al., 2006a; Strizzi et al., 2008). While Nodal is undetectable in normal
melanocytes, it has been shown to become minimally expressed in poorly invasive, radial
growth phase melanoma and highly expressed in invasive vertical growth phase
melanoma and metastatic melanoma (Topczewska et al., 2006). Furthermore, inhibition
of Nodal signaling via the small molecule inhibitory drug, SB431542, or morpholino
oligonucleotides led to a significant reduction in metastasis and tumour formation, as
well as a loss of plasticity, as indicated by upregulation of Tyrosinase and
downregulation of Vascular Endothelial (VE)-Cadherin and Keratin 18, resulting in a
more differentiated melanocyte-like cell (Topczewska et al., 2006).
Nodal expression has also been implicated in breast cancer. Immunohistochemical
analysis of human breast tissue microarrays revealed that Nodal has a significant positive
correlation with breast cancer progression, being completely absent in normal beast tissue
(Postovit et al., 2008). Nodal knock-down via morpholino oligonucleotides, shRNA, or
the small molecule inhibitor SB431542 in the highly aggressive MDA-MB-231 breast
cancer cell line, decreased invasion and clonogenicity in vitro and tumorigenicity in nude
mice (Quail et al., 2010). Correspondingly, when MDA-MB-231 are treated with
conditioned medium from hESC containing Lefty, these functional capabilities
decreased, concomitant with reduced Nodal mRNA and protein expression (Postovit et
al., 2008). Conversely, treatment of the poorly aggressive human breast cancer cell line,
T47D with human recombinant Nodal resulted in an increase in invasion, self-renewal
and anchorage independent growth (Quail et al., 2010). Furthermore, the phenotypic
plasticity of the commonly designated CD44+/CD24- breast cancer stem cell (Al-Hajj et
al., 2003) has been shown to be mediated by the Nodal/Activin signaling pathway, as
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treatment of this population with the small molecule inhibitor, SB431542 significantly
inhibited its ability to undergo phenotypic switching (Meyer et al., 2009).
Following the above results suggesting that the embryonic stem cell derived Lefty
can inhibit the tumorigenicity of cancer cells, Cavallari and colleagues (2012) wanted to
determine if adult stem cells also possess this anti-tumoral property. They demonstrate
that conditioned medium from human liver stem cells (HLSC-CM) inhibits the in vitro
growth and promotes apoptosis in the hepatoma cell line, HepG2 and this effect was
attributed to the presence of Lefty A in the HLSC-CM, as silencing Lefty A abrogated the
anti-proliferative and pro-apoptotic effects. Furthermore, intra-tumor administration of
HLSC-CM inhibited the in vivo growth of HepG2 cells in SCID mice. Conversely, CM
from bone marrow-derived mesenchymal stem cells did not produce this anti-tumor
effect, suggesting only certain adult stem cells are able to inhibit tumor growth through
inhibition of the Nodal signaling pathway, similar to embryonic stem cells (Cavallari et
al., 2012).
Nodal signaling has also been linked to endometrial cancer (Papageorgiou et al.,
2009). This study showed that while Nodal and its co-receptor, Cripto, are expressed in
the stroma and epithelium of the endometrium during the normal proliferative phase of
the menstrual cycle, they are significantly upregulated in patient biopsies of endometrial
carcinoma and show a positive correlation with cancer grade (Papageorgiou et al., 2009).
Additionally, Nodal’s endogenous inhibitor, Lefty, was present in normal epithelium and
surrounding stroma during the late secretory and menstrual phases, however was not
present in endometrial cancer tissues (Papageorgiou et al., 2009).
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Nodal has similarly been found to correlate with highly invasive glioma cells (Lee
et al., 2010). These authors found a positive correlation between Nodal expression and
grade in human glioma tissue (Lee et al., 2010). Additionally, when they overexpressed
Nodal in glioma cells exhibiting low endogenous levels of Nodal, they found a significant
increase in invasion, MMP-2 secretion/activity, proliferation in vitro, and tumour growth
in vivo (Lee et al., 2010). Furthermore, when Nodal was knocked down in glioma cells
expressing high endogenous levels of Nodal, there was a significant decrease in invasion,
MMP-2 section/activity, proliferation in vitro, and tumour growth in vivo (Lee et al.,
2010).
Recent work in pancreatic cancer has also implicated an important role for Nodal
and Activin signaling (Lonardo et al., 2011). This group found elevated levels of both
Nodal and Activin in pancreatic “cancer stem cells” (CSC) that formed non-adherent
spheroids and expressed pluripotency markers, compared to more differentiated adherent
pancreatic cancer cells (Lonardo et al, 2011). The addition of recombinant Nodal to these
CSCs increased spheroid formation, size, and invasion in vitro, while inhibition of
Nodal/Activin signaling with SB431542 eliminated the CSC subpopulation and increased
susceptibility to gemcitabine chemotherapy in vitro, and in vivo in an orthotopic mouse
model (Lonardo et al., 2011).
The pro-metastatic role of Nodal is not so clear-cut. One study of ovarian cancer
found that Nodal overexpression resulted in a decrease in the number of metabolically
active and proliferating cells (Xu et al., 2004). This was attributed to the upregulation of
cyclin G2 (CCNG2) (Xu et al., 2008) via the Forkhead box class O transcription factor,
FoxO3a (Fu & Peng, 2011). They found that when ovarian surface epithelium cells,
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IOSE-394, and ovarian cancer cells, OV2008, were treated with recombinant Nodal or
transfected with Nodal plasmid DNA, there was a significant increase in FoxO3a proteins
levels, while silencing of ALK7 or Smad4 using small interfering RNAs (siRNAs)
decreased protein levels. Using IP assays they then showed that Smad2/3 forms a
complex with FoxO3a and that this complex binds the promoter of CCNG2 to enhance
transcription (Fu & Peng, 2011). While these findings appear contradictory to the widely
reported pro-metastatic role of Nodal in cancer, it has been noted that overexpression of
Nodal in cancer cells already expressing Nodal tends to promote apoptosis, whereas
overexpression of Nodal in cancer cells that do not express Nodal tends to favour
metastases (Quail et al., 2010a). These seemingly contradictory results shed light on the
concentration-dependent multi-functionality of Nodal signaling. This is consistent with
other members of the TGF-β superfamily, which have various concentration-dependent
effects during embryonic development and cancer progression (Hoffman, 1992;
Soderberg et al., 2009; Tian & Schiemann, 2009; Bachman & Park, 2005).
1.2.5 Nodal and Placentation
As mentioned above, Nodal, its co-receptor Cripto, and its inhibitor, Lefty, are all
found within normal endometrial stromal and epithelial cells during various stages of the
menstrual cycle (Papageourgiou et al., 2009). Nodal mRNA was found to be highest
during the proliferative and early secretive phases and almost completely absent by the
mid-secretory phase, while Lefty mRNA appears beginning in the late-secretory phase
and continues throughout menstruation, after which it disappears with the reappearance
of Nodal in the early-proliferative phase. Cripto on the other hand was expressed
throughout the cycle, increasing in expression from the early-proliferative phase until the
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late secretory phase, after which it rapidly decreases during menses (Papageorgiou et al.,
2009). Additionally, Nodal expression is also observed in the mouse and human
placentae (Ma et al., 2001; Nadeem et al., 2011). In the mouse, Nodal mRNA is restricted
to the spongiotrophoblast compartment (Ma et al., 2001), however in the human, Nodal
protein has been localized within all trophoblast lineages, with expression greatest in the
cytotrophoblasts (Nadeem et al., 2011). Nodal expression was found to decrease during
the progression of pregnancy, being absent in the syncytiotrophoblast and extravillous
trophoblast and only minimally expressed in the cytotrophoblast by the third trimester
(Nadeem et al., 2011).
In addition to its presence in the placenta, a role for Nodal during placentation has
been indicated by the aberrant placental development observed in the Nodal null
homozygous mouse. These placentae displayed enlargement of the polyploid giant cell
layer at the expense of the diploid spongiotrophoblast and labyrinth layers (Ma et al.,
2001). Additionally, expression of Nodal was found to inhibit trophoblast giant cell
differentiation in the rat choriocarcinoma cell line, Rcho-1 (Ma et al., 2001). Following
these findings, the authors postulated that Nodal functioned to direct trophoblast fate
towards the labyrinth lineage, while maintaining the thin layers of giant cells and
spongiotrophoblast (Ma et al., 2001). More recent work, however, demonstrated that
Nodal, acting through FGF4, maintains a microenvironment that inhibits mouse
trophoblast stem cell differentiation (Guzman-Ayala et al., 2004). This work has since
translated to human studies, with establishment of the first human trophoblast progenitor
cell line using the Nodal/Activin inhibitor, SB431542 (Genbacev et al., 2011). The
rational being that inhibiting Nodal signaling in the trophoblast stem cell population
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would decrease expression of pluripotency factors as well as enable the emergence of
more differentiated progenitor cells. It may be the case that a Nodal gradient is present in
which the more pluripotent trophoblast stem cells express high Nodal levels, bi-potential
cytotrophoblast progenitors moderate levels, and differentiated trophoblasts little to no
Nodal.
Nodal and its receptor, ALK7, have been detected in the placenta throughout
gestation, suggesting it regulates differentiated trophoblasts, in addition to TSCs (Roberts
et al., 2003). Roberts and colleagues were the first to demonstrate that ALK7 and Nodal
transcripts are expressed in the placenta throughout gestation (weeks 6-40), with Nodal
expression being highest between weeks 12-29 (Roberts et al., 2003). Additionally, they
discovered that the ALK7 receptor transcript is alternatively spliced, yielding four
isoforms (ALK7, tALK7, sALK7a, sALK7b) all of which are translated to protein
(Roberts et al., 2003). The full-length ALK7 and truncated ALK7 were also expressed
throughout gestation, with expression of truncated ALK7 significantly increasing in the
third trimester of pregnancy, while the soluble forms of ALK7 showed variable
expression. As the truncated isoform may possess reduced affinity for the ligand, it was
postulated to act as an antagonist of full-length ALK7, reducing Nodal signaling during
the later stages of pregnancy (Roberts et al., 2003).
Work in human trophoblast and choriocarcinoma cell lines has implicated a role
for Nodal in the regulation of trophoblast proliferation and apoptosis. Nodal overexpression was found to decrease the number of actively proliferating cells while
increasing the number of apoptotic cells. Furthermore, constitutively active ALK7 was
found to recapitulate these effects, while a kinase-deficient ALK7 or dominant-negative
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Smad2/3 was found to block the effects (Munir et al., 2004). Trophoblast migration and
invasion were also affected by Nodal signaling. In this case, Nodal over-expression or
constitutively active ALK7 decreased cell migration and invasion, while Nodal or ALK7
knock-down had the reverse effect (Nadeem et al., 2011). In placental explant culture,
treatment with recombinant human Nodal was shown to inhibit trophoblast outgrowth,
while Nodal small-interfering RNA increased EVT migration. The inhibitory effects of
Nodal were found to be mediated by increased secretion of tissue inhibitor of
metalloproteinase (TIMP)-1 and inhibited matrix metalloproteinase (MMP)-2 and MMP9 activity (Nadeem et al., 2011). Taken together, these results indicate an important role
for Nodal/ALK7 signaling in human placentation.
Given the importance of Nodal signaling in placental development, it is not
surprising that Nodal and members of the Nodal signaling pathway have been implicated
in placental disorders. For example, the Nodal antagonist Lefty has been associated with
impaired implantation and infertility. Tabibzadeh and colleagues (2000) demonstrated
that in contrast to normal fertile women who exhibit low levels of Lefty protein in the
endometrium during the receptive phase, infertile women expressed significantly higher
levels of Lefty during this phase. Furthermore, successful pregnancy occurred when
treatment of these infertile women involved the downregulation of Lefty (Tabibzadeh et
al., 2000). This group went on to study implantation in mice and found that when they
transfected Lefty, either by retroviral vector or liposome-mediated DNA transfer, into the
uterine horns of pregnant mice, implantation failure occurred (Tang et al., 2005). This
implantation failure was associated with a lack of decidualized stroma suggesting Lefty
plays an important role in this process, however an affect of Lefty on extraembryonic
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tissues remains possible (Tang et al., 2005). Seemingly contradictory to this, work in the
Peng lab has shown that Nodal and ALK7 are strongly upregulated in the placentae of
women with preeclampsia, a multisymptomatic disease thought to arise from reduced
trophoblast invasion (Nadeem et al., 2011). This is in accordance with their findings that
Nodal has an inhibitory effect on trophoblast proliferation, migration and invasion (Munir
et al., 2004; Nadeem et al., 2011). While it is apparent that Nodal signaling plays an
important role in implantation and placentation, controversy remains over exactly how
Nodal regulates trophoblast differentiation and how this affects placentation.
1.3 Rationale
	
  

As reviewed earlier, loss of α6β4 integrin is one of the hallmarks of the transition

of trophoblast progenitors to EVT cells in situ. This phenomenon has been faithfully
recapitulated in vitro, showing that EVT cells migrating out of chorionic villus explants
in culture (Irving et al., 1995) as well as short-lived primary EVT cell lines including
HTR-8 cells (Irving & Lala, 1995) had a paucity of α6β4 expressing cells. In contrast, a
detailed analysis of the integrin profile of several SV40 Tag immortalized derivatives of
HTR-8 cells, including HTR-8/SVneo, RSVT-2 and RSVT-2C cell lines revealed a
significant incidence of α6β4 expressing cells. This indicated SV40 Tag integration in
the small α6β4 bearing pool in HTR-8 cells leading to immortalization (Lala et al., 1995
abstract). Of the above three immortalized cell lines, two (RSVT-2 and RSVT-2C) were
shown to have acquired a premalignant phenotype, whereas HTR-8/SVneo cell line
remained normal except for immortalization (Khoo et al., 1998a; Khoo et al., 1998b; Lala
et al., 1999).
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Preliminary work by others in the lab has validated these findings in HTR8/SVneo cells, showing that similar to the progenitors in situ, a subpopulation of these
cells express α6β4 integrin (Figure A1-A,B). Furthermore, an α6β4high subpopulation can
be isolated using Fluorescence Activated Cell Sorting (FACS), a method for sorting a
heterogeneous cell line into two or more subpopulations based upon the specific light
scattering and immunofluorescent characteristics of each cell (Figure A2-A,B). This
α6β4high subpopulation has been shown to have a significantly higher colony formation
capacity than the heterogeneous HTR-8/SVneo population, while the α6β4low
subpopulation has a lower clonogenic capacity relative to the α6β4high and heterogeneous
cells (Figure A3-A). Additionally, compared to the unsorted and α6β4low, the α6β4high
cells are better able to differentiate along the villous pathway, as exhibited by hCG
expression (Figure A3-B) and extravillous pathway, exemplified by enhanced invasion
(Figure A3-C) and endovascular differentiation including VE-Cadherin expression
(Figure A3-D) and endothelial tube-like formation (Figure A3-E) (Zhong et al., 2008).
This cell line also expresses Nodal, an embryonic morphogen and stem cellassociated factor that sustains the pluripotency of embryonic stem cells. While Nodal is
expressed in both the endometrium (during the peri-implantation period) and the placenta
(throughout the first trimester of pregnancy), and has been shown to play roles in
regulating trophoblast proliferation/apoptosis and migration/invasion, its precise role in
regulating cytotrophoblast differentiation remains unclear.
Thus, in this study I examined the effects of Nodal on the regulation of α6β4high
cytotrophoblast progenitor cells, as well as their ability to undergo differentiation along
the villous and extravillous trophoblast lineages.
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1.4 Hypothesis
The α6β4high subset within HTR-8/SVneo is enriched with bi-potential cytotrophoblast
progenitor-like cells that are maintained by Nodal signaling.
The study consists of three aims:
1.

To isolate and characterize proliferation and Nodal expression in α6β4high
HTR-8/SVneo cytotrophoblasts.

2.

To examine effects of loss of function of Nodal on hallmarks of
cytotrophoblast progenitors: (1) expression of integrin α6β4, (2) self renewal
& proliferation, and (3) differentiation capacity along both villous and
extravillous pathways.

3.

To examine effects of gain of function of Nodal on cytotrophoblast progenitor
hallmarks.
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Materials: RPMI 1640, DMEM, and F-12K medium, fetal bovine serum (FBS),
Dulbecco’s phosphate-buffered saline (DPBS), and 0.05% Trypsin-EDTA, and
puromycin used in cell culture were purchased from Invitrogen. BD Falcon cell culture
flasks (150cm2 and 75cm2), 6-well plates, 12-well plates, and growth factor reduced
(GFR) matrigel were from BD Biosciences. Gentamicin was from HyClone Laboratories.
Geneticin was from Gibco. M-PER® Mammalian Protein Extraction Reagent, HALTTM
Protease Inhibitor Cocktail and RestoreTM Plus Western blot stripping buffer were from
Pierce. Anti-Nodal antibody (clone WS65) was from Santa Cruz Biotechnology. Anti-βActin primary antibody, and goat anti-rabbit IgG and goat anti-mouse IgG secondary
antibodies was from LI-COR Biosciences. Bovine serum albumin (BSA) and SB431542
(Nodal/Activin Inhibitor) were purchased from Sigma. Recombinant human Nodal was
from R&D Systems. Human ELISA kit for hCG (BQ047F) was from BioQuant. RNeasy
Mini Kit from Qiagen, High Capacity cDNA Reverse Transcription Kit and Master Mix
from Applied Biosystems.

Cell Culture: HTR-8/SVneo cells were grown in RPMI medium 1640 supplemented
with 10% FBS, 100 µg/ml gentamicin, unless otherwise specified, at 37°C and 5% CO2.
Stable Nodal knock-down HTR-8/SVneo cells and scrambled control cells were
generated by transfection via lipofectamine of a pGIPZ lentiviral vector (Open
Biosystems) containing either an shRNANodal (GI311709, clone 6) or shRNAscramble
(TR30013). Clones were selected with 500 ng/ml puromycin. Cells were grown in RPMI
1640 supplemented with 10% FBS, 100 µg/ml gentamicin, and 200ng/ml puromycin at
37°C and 5% CO2 unless otherwise specified. Successful transfection was verified by
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GFP immunofluorescence. Nodal knock-down was verified by Western blot in
comparison to scramble control-transfected cells. The choriocarcinoma cell line, BeWo
(ATCC) were grown in DMEM supplemented with 10% FBS and 100 µg/ml gentamicin
unless otherwise specified, at 37°C and 5% CO2. Stable Nodal over-expressing BeWo
clones were generated by transfection with Arrest-In of a pcDNA3.3-TOPO vector (Life
Technologies) containing the Nodal open reading frame cloned from H9 hESCs. Clones
were selected with 500 µg/ml Geneticin. Cells were grown in DMEM supplemented with
10% FBS, 100 µg/ml gentamicin and 100 µg/ml Geneticin unless otherwise specified, at
37°C and 5% CO2. Successful Nodal over-expression was verified by Western Blot in
comparison to non-transfected parental cells. All transfections completed by Guihua
Zhang.	
  

Fluorescence Activated Cell Sorting (FACS): HTR-8/SVneo cells grown in complete
medium (RPMI 1640, 10% FBS, and gentamicin) were washed, trypsinized and
centrifuged for 5 min at 2,500 RPM. The cells were then re-suspended in FACS buffer
(DPBS + 3% FBS) to a concentration of approximately 10 million cells/ml and 100µl
aliquots were incubated in monoclonal FITC-conjugated rat Anti-Human CD49f (α6)
(BD Pharmingen) and PE-conjugated rat Anti-Human CD104 (β4) (BD Pharmingen)
(including the appropriate isotype controls) on ice for 1 hour in the dark. Cells were then
washed twice with FACS buffer and resuspended/pooled in 4 ml for a final concentration
of 5 million cells/ml. The cell suspension was brought to the London Regional Flow
Cytometry Facility for FACS analysis. The resulting α6β4high and α6β4low populations
were then plated and incubated at 37°C, 5% CO2 for 24hrs until analysis. For flow
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cytometry, cells were prepared as above, except incubated in monoclonal PE-Cy5conjugated rat Anti-Human CD49f (α6) (BD Pharmingen) and PE-conjugated rat AntiHuman CD104 (β4) (BD Pharmingen) (including the appropriate isotype controls) and
resuspended in 0.5ml for a final concentration of 2 million cells/ml. Flow cytometry was
conducted at the London Regional Flow Cytometry Facility. Quadrant gates set according
to isotype controls were used to determine positive populations; gates set according to the
top 20% of the singlet population in the appropriate control cells were used to determine
the percentage of α6β4high cells in the Nodal knock-down and over-expressing cells.

Cell Growth Assay: Cells were plated into 6-well plates at a density of 1 X 104 cells per
well in triplicate and incubated in complete medium at 37°C. Cell numbers were
determined on days 1, 3, 5, 7 and 9 by hemocytometry. Doubling time was calculated at
! !!!

!
mid-exponential phase according to the formula: DT = !.!"(!"#!

! !!"#!! )

where !! is

initial time point, !! is final time point, !! is initial cell number, and !! is final cell
number (McAtier & Daview, 1998).

BrdU Cell Proliferation Assay: Cells were plated into 96-well plates at a density of 2 X
103 cells per well and incubated for 24h at 37°C. The 5-bromo-20-deoxy-uridine (BrdU)
proliferation assay was performed as described by the manufacturer (Roche). Briefly,
20µl/well of BrdU labeling solution was added to cells and incubated for 24hr at 37°C.
Cell were then fixed with 100µl fix solution for 1hr at room temperature followed by
incubation with anti-BrdU antibody conjugated with peroxidase for 90 min. A substrate
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solution was then added to each well, and absorbance was measured at 370nm with a
reference wavelength at 492nm using an ELISA plate reader.

Viability/Cytotoxicity Assay: Cells were plated into 96-well plates at a density of 3.25 X
102 cells per well and incubated for 1, 3, 5, 7 and 9 days at 37°C to mimic the cell
densities of the manual counting growth assay. The LIVE/DEAD assay was performed as
described by the manufacturer (Life Technologies). Briefly, dead control wells were
treated with DMSO and incubated for 15 min. Live control wells were washed 3X with
DPBS. Wells were then labeled with 100 µl/well of appropriate dye solution and
incubated for 45 min at room temperature in the dark. Fluorescence was then measured
using a microplate reader (FLUOstar Omega, BMG Labtech).

Limiting Dilution Clonogenicity Assay: Cell suspensions were serially diluted in
complete medium to a final concentration of 10 cells/ml. The equivalent of one cell, or
100 µl, was added per well of a 96 well plate and incubated at 37°C for 7-14 days. Cells
treated with rhNodal or SB431542 were treated on days 0, 3, 6, and 9 if applicable.
Clonogenicity was assessed by counting the number of colony positive wells; a well is
considered positive when it contains a colony with 32 or more cells.

RT-qPCR: Total RNA was extracted after specific treatments using RNeasy Mini Kit.
Respective cDNA was synthesized using the High Capacity cDNA Reverse Transcription
Kit, and real time quantitative PCR analysis was performed using 2ug of cDNA and
TaqMan® gene expression human primer/probe sets. Primer/probes included Nodal
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(Nodal; Hs00250630_s1), hCG (CGB; Hs00361224_gH), and VE-Cadherin (CDH5;
Hs00174344_m1). HPRT1 primer/probe was from Applied Biosystems (43337681005027). To determine the relative quantitation of gene expression, the comparative
threshold cycle method (2-ΔΔCt) was used (Pfaffl, 2001). The final mRNA levels were
normalized according to their Ct values from the standard curves and expressed in
relation to respective HPRT1 level.

Western Blot Analysis: Cells were washed with ice-cold DPBS and lysed in M-PER®
lysis buffer supplemented with HALTTM protease inhibitor cocktail. Cell lysates were
sonicated, centrifuged and supernatant protein was quantified using the BCA protein
assay kit as described by the manufacturer. Equal amounts of protein (5-10ug) were
separated on 10% SDS-PAGE gels and transferred to a PVDF membrane. Membranes
were blocked in 0.5% non-fat milk in TBS-T (20mM tris-base, 0.14M NaCl, pH 7.8,
0.1% Tween-20) at 4°C, overnight. Membranes were probed for Nodal (Santa Cruz,
clone WS65; 100 ng/ml) for 1 hr at room temperature, then washed with TBS-T and
incubated in fluorescent-conjugated rabbit or mouse secondary antibodies (LiCor,
polyclonal; 50 ng/ml) for one hour at room temperature in the dark. Fluorescence was
detected using the Odyssey Infrared Imager (Mandel). All experiments were performed at
least 3 times.

Syncytialization: Cells were grown in F-12K medium containing 10% FBS with or
without 50uM Forskolin. Syncytialization was quantified according to hCG expression as
measured by qRT-PCR and ELISA.
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Endothelial-like Tube Formation Assay: Growth factor reduced (GFR) matrigel,
diluted 1:1 with basal RPMI 1640 media, was added to 12-well plates and incubated for
1hr at 37°C to solidify. Cells in serum free RPMI were seeded on the matrigel-coated
plates (100,000 cells per plate) and incubated at 37°C, 5% CO2 for 24 hours. Pictures
were taken after 18 hours of three random fields of view using a Leica EC3 camera. The
total number of branch points was quantified using the NIH ImageJ software.

Gene/miRNA Array: Single stranded complimentary DNA (sscDNA) was prepared
from 200 ng of total RNA as per the Ambion WT Expression Kit for Affymetrix
GeneChip Whole Transcript WT Expression Arrays and the Affymetrix GeneChip WT
Terminal Labeling kit and Hybridization User Manual. Total RNA was converted to
cDNA, followed by in vitro transcription to make cRNA. 5.5 ug of single stranded
cDNA was synthesized, end labeled and hybridized, for 16 hours at 45°C, to Human
Exon 1.0 ST arrays. One microgram of total RNA was labeled using the Flash Tag Biotin
HSR kit from Genisphere. Samples were then hybridized to Affymetrix miRNA 2.0
arrays for 16 hours at 45°C. All washing steps were performed by a GeneChip Fluidics
Station 450 and GeneChips were scanned with the GeneChip Scanner 3000 7G
(Affymetrix, Santa Clara, CA) using Command Console v1.1. Probe level (.CEL file)
data was generated using Affymetrix Command Console v1.1. Probes were summarized
to miRNA or gene level in Partek Genomics Suite v6.6 (Partek, St. Louis, MO) using the
RMA algorithm (Irizarry et al., 2003). Partek was used to determine ANOVA p-values
and fold changes for genes and fold changes for miRNAs. Species annotations were
added and used to filter only those miRNAs found in Homo sapiens. The gene targets for
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increased Homo sapiens miRNAs were determined using TargetScan v5.2 and correlated
with 1.5 fold, p-value 0.05 decreased genes.

Statistical Analysis: Data are presented as mean ± standard error (SEM) for parametric
data, and median ± interquartile range (IQR) for nonparametric data. Parametric data was
analyzed by a one-way ANOVA followed by a post-hoc TUKEY’s test using Graph Pad
Prism 5 software, while nonparametric data was analyzed by a one-way ANOVA on
ranks followed by a post-hoc Dunn’s test using SigmaStat 3.5. Differences between two
treatment groups were considered significant at P < 0.05.
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Chapter Three: Results
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The α6β4high subset of HTR-8/SVneo expresses higher levels of Nodal protein compared
to the α6β4low subset
Following the preliminary results suggesting the α6β4high subset of HTR-8/SVneo
contains a more phenotypically plastic population compared to the α6β4low and unsorted
control cells, we sought to determine whether Nodal expression correlates with this more
progenitor-like phenotype. FACS analysis was used to isolate α6β4high and α6β4low
subpopulations from HTR-8/SVneo cells (Figure 5-A,B) and Nodal expression was
measured at the mRNA and protein level using qRT-PCR and Western blot analysis,
respectively (Figure 5-C,D). The α6β4high subpopulation expressed higher levels of Nodal
protein compared to the α6β4low subpopulation, but similar levels compared to the
unsorted control cells. These results were passage dependent, as later passages exhibited
no change in Nodal protein. Interestingly, Nodal protein expression did not correlate with
mRNA levels, as there was no significant difference in Nodal mRNA expression between
the three populations examined (Figure 5-C).
The α6β4high and α6β4low subsets of HTR-8/SVneo display equal rates of growth and
proliferation
We next sought to determine whether this progenitor-like phenotype and Nodal
protein expression correlated with proliferation. Growth rate was measured via manual
counting and proliferation via the BrdU assay. The doubling times for the α6β4high and
α6β4low subsets were 23.4 and 26.1 hours, respectively, which were not significantly
different (P = 0.274, n = 3, Figure 6-A). Accordingly, BrdU analysis also revealed no
significant difference in proliferation between the α6β4high and α6β4low subsets (Figure 6B).
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Figure 5. Integrin α6β4high cells express higher levels of Nodal protein compared to
α6β4low cells.
HTR-8/SVneo cells (A) were harvested and incubated with IgG isotype controls, FITC
conjugated rat anti-human CD49f IgG (specific for α6 integrin chain) and/or PE
conjugated rat anti-human CD104 (specific for β4 integrin chain). FACS analysis was
used to isolate α6β4high (top 20%) and α6β4low (bottom 20%) of unsorted singlet
population (B). RNA was isolated immediately following FACS. cDNA was synthesized
and qRT-PCR was used to quantify Nodal mRNA expression relative to the HPRT1
housekeeping gene (C). Nodal mRNA was equivalent within the three cell populations
examined. Cell lysates were prepared immediately following FACS and analysed for
Nodal protein by Western blot (D). Nodal protein was higher in α6β4high cells compared
to α6β4low cells, while lower in α6β4low cells compared to unsorted control cells. qRTPCR data are represented as a median ± interquartile range (IQR) for three independent
experiments. Different characters indicate significant differences (p<0.05).
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Figure 6. Integrin α6β4high cells do not exhibit altered growth rate or proliferation
relative to α6β4low and unsorted controls.
Integrin α6β4high and α6β4low subpopulations were isolated by FACS from HTR8/SVneo cells and plated at 104 cells/well in 6-well plates in triplicate and incubated at at
37°C, 5% CO2. Cells were harvested and manually counted using a haemocytometer on
alternate days from day 1 to day 9 (A). The α6β4high subpopulation did not exhibit an
altered rate of growth relative to the α6β4low subpopulation, as the doubling times were
23.3 and 26.1 hours, respectively (P=0.274). Cells were also plated at 2 x 103 cells/well
of 96-well plates in complete RPMI. Cells were incubated at 37°C, 5% CO2 for 24 hours.
BrdU labeling solution was added to the culture medium and cells were further incubated
for 24 hours. Cells were fixed with 100 ul/well fix solution for 30 min at room
temperature and incubated with anti-BrdU antibody conjugate with peroxidase for 90
min. A substrate solution was then added into each well, and absorbance was measured
(B). Similarly, proliferation in the α6β4high cells was not significantly different from that
of either α6β4low or unsorted control cells. Proliferation data are represented as a median
± interquartile range (IQR) for five independent experiments with each condition
measured 8 times. Different characters indicate significant differences (p<0.05).
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Nodal sustains a higher level of α6β4high expressing cells
As the α6β4high expressing cells were found to express higher levels of Nodal protein
relative to the α6β4low expressing cells, we were interested in determining whether Nodal
expression correlates with expression of integrin α6β4. HTR-8/SVneo cells stably
transfected with Nodal shRNA were generated (Figure 7-A) and flow cytometry analysis
was completed for the α6 and β4 integrin chains. Knock-down of Nodal was verified by
Western blot analysis (Figure 7-B). Nodal knock-down resulted in a decreased shift in
intensity of both α6 and β4 integrin chains (Figure 8-A). Examining the α6 and β4
subunits separately, the median intensity of the α6 subunit decreased by approximately
1.6-fold, while the median intensity of the β4 subunit decreased by 2-fold and was
significantly different from controls (Figure 8-B,C,D). Following our observations with
Nodal knock-down on the expression of α6 and β4 integrin chains, we were interested in
determining the effect of Nodal over-expression. To do so, BeWo cells were transfected
with a plasmid containing the Nodal open reading frame (Figure 9-A) and flow cytometry
analysis for the α6 and β4 integrin chains was completed as above. BeWo were chosen as
previous studies have shown they express low levels of Nodal relative to HTR-8/SVneo.
Over-expression of Nodal was verified by Western blot analysis (Figure 9-B). As
expected, Nodal over-expression caused an upward shift in the intensity of both α6 and
β4 integrin chains (Figure 10-A). The median intensity of the α6 subunit increased 1.7fold, while that of the β4 subunit increased by 1.6-fold (Figure 10-B,C,D).
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Figure 7. Stable Nodal knock-down in HTR-8/SVneo trophoblast cells.
HTR-8/SVneo cells were harvested and transfected via lipofectamine with a pGIPZ
lentiviral vector containing either an shRNANodal or shRNAscramble control (A). Cell
lysates were prepared and analyzed for Nodal protein by Western blot (B). Nodal protein
(50 and 37kDa) decreased in the Nodal knock-down cells (shNodal) compared to
scrambled control cells (shSCR).
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Figure 8. Nodal knock-down decreases expression of integrin α6β4.
HTR-8/SVneo scrambled control (shSCR) and shRNANodal knock-down (shNodal) cells
were harvested and incubated with IgG isotype controls, PE-Cy5 conjugated rat antihuman CD49f IgG (specific for α6 integrin chain) and/or PE conjugated rat anti-human
CD104 (specific for β4 integrin chain). Flow cytometry was used to examine expression
of the α6 and β4 integrin subunits. Scatter plots of the intensity of α6 and β4 subunits
contain square gates to designate top 20% of control cells and represent α6β4high cells
(A). Nodal knock-down caused a decrease in the intensity α6β4 expression. Histograms
display intensity of α6 and β4 subunits separately (B). Expression of the α6 and β4
subunits decreased by 1.6 and 2-fold, respectively (C,D). Flow cytometry data are
represented as a median ± interquartile range (IQR) for three independent experiments.
(*) indicates significant differences (p<0.05).
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Figure 9. Stable Nodal over-expression in BeWo choriocarcinoma cells.
BeWo cells were harvested and transfected with Arrest-In with a pcDNA3.3-TOPO
vector containing the Nodal open reading frame cloned from H9 hESCs (A). Cell lysates
were prepared and analyzed for Nodal protein by Western blot (B). Nodal protein
(37kDa) increased in the Nodal over-expressing cells (NOE) compared to BeWo parental
(BeWo) cells.
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Figure 10. Nodal over-expression increases expression of integrin α6β4.
BeWo parental (BeWo) and Nodal over-expressing (NOE) cells were harvested and
incubated with IgG isotype controls, PE-Cy5 conjugated rat anti-human CD49f IgG
(specific for α6 integrin chain) and/or PE conjugated rat anti-human CD104 (specific for
β4 integrin chain). Flow cytometry was used to examine expression of the α6 and β4
integrin subunits. Scatter plots of the intensity of α6 and β4 subunits contain square gates
to designate top 20% of control cells and represent α6β4high cells (A). Nodal overexpression caused an increase in the intensity α6β4 expression. Histograms display
intensity of α6 and β4 subunits separately (B). Expression of the α6 and β4 subunits
increased by 1.7 and 1.6-fold, respectively (C,D). Flow cytometry data are represented as
a median ± interquartile range (IQR) for three independent experiments. (*) indicates
significant differences (p<0.05).
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Nodal expression maintains colony forming capacity in HTR-8/SVneo & BeWo
In order to determine if Nodal plays a role in HTR-8/SVneo colony formation, a
limiting dilution clonogenic assay was performed. Nodal knock-down significantly
decreased HTR-8/SVneo colony forming capacity and this effect of Nodal knock-down
was partially rescued via treatment with 100ng/mL rhNodal (Figure 11). Conversely,
Nodal over-expression in BeWo significantly increased colony forming capacity and this
effect of Nodal over-expression was partially reversed by treatment with 10 µM of the
Nodal/Activin inhibitor, SB431542 (Figure 12).
Nodal expression differentially regulates HTR-8/SVneo and BeWo proliferation
As Nodal appears to increase colony formation capacity, we sought to determine
if this was associated with an affect on proliferation. Growth and proliferation were
assayed by manual counting and the BrdU assay, respectively. Nodal knock-down in
HTR-8/SVneo significantly decreased the rate of growth as the doubling time increased
from 32.2 to 54.0 hours (P=0.015, n = 3, Figure 13-A). Conversely, in the BrdU
proliferation assay, Nodal knock-down significantly increased proliferation by 12%,
while treatment with recombinant human Nodal partially reversed this phenotype,
although this was not significant (Figure 13-B). In contrast to HTR-8/SVneo, Nodal overexpression had no significant effect on BeWo doubling time, with BeWo parental cells
doubling every 24.5 hours while the Nodal over-expressing cells doubled every 20.3
hours (P=0.101, n = 3, Figure 14-A). Similarly, BeWo proliferation measured by BrdU
assay was also not significantly different (Figure 14-B).
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Figure 11. Nodal knock-down reduces HTR-8/SVneo clonogenicity.
HTR-8/SVneo scrambled control (shSCR) and shRNANodal knock-down (shNodal) cells
were serially diluted and plated at one cell per well of 96 well plate in complete RPMI.
shNodal cells were also plated in the presence of 100ng/ml recombinant human Nodal
(rNodal). Nodal knock-down significantly decreased colony formation, while the
presence of rNodal partially rescued the phenotype. Clonogenicity data are represented as
a median ± interquartile range (IQR) for three independent experiments. Different
characters indicate significant differences (p<0.05).

52	
  

Relative Colony Formation
(Median +/- IQR)

	
  

30

b

20

a,b

10

a
0
BeWo

NOE

NOE +
SB431542
	
  

Figure 12. Nodal over-expression increases BeWo clonogenicity.
BeWo parental (BeWo) and Nodal over-expressing (NOE) cells were serially diluted and
plated at one cell per well of 96 well plate. NOE cells were also plated in the presence of
10 µM Nodal/Activin inhibitor, SB431542. Nodal over-expression significantly increased
colony formation, while the presence of Nodal/Activin inhibitor partially inhibited colony
formation. Clonogenicity data are represented as a median ± interquartile range (IQR) for
three independent experiments. Different characters indicate significant differences
(p<0.05).
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Figure 13. Nodal knock-down decreases HTR-8/SVneo growth rate but increases
proliferation.
HTR-8/SVneo scrambled control (shSCR) and shRNANodal knock-down (shNodal) cells
were plated at 104 cells/well in 6-well plates in triplicate and incubated at at 37°C, 5%
CO2. Cells were harvested and manually counted using a haemocytometer on alternate
days from day 1 to day 9 (A). Growth rate was determined relative to day 1 cells counts.
Nodal knock-down significantly decreased the rate of growth with doubling time
increasing from 32.2 to 54.0 hours (P=0.015). Cells were also plated at 2 x 103 cells/well
of 96-well plates in complete RPMI. Cells were incubated at 37°C, 5% CO2 for 24 hours.
BrdU labeling solution was added to the culture medium and cells were further incubated
for 24 hours. Cells were fixed with 100 ul/well fix solution for 30 min at room
temperature and incubated with anti-BrdU antibody conjugate with peroxidase for 90
min. A substrate soltion was then added into each well, and absorbance was measured
(B). Nodal knock-down significantly increased proliferation, while the Nodal/Activin
inhibitor, SB431542 partially rescured this phenotype. BrdU proliferation data are
represented as a median ± interquartile range (IQR) for five independent experiments
with each condition measured 8 times. Different characters indicate significant
differences (p<0.05).

54	
  

	
  

	
  
Figure 14. Nodal over-expression does not affect BeWo growth or proliferation.
BeWo parental (BeWo) and Nodal over-expressing (NOE) cells were plated at 104
cells/well in 6-well plates in triplicate and incubated at at 37°C, 5% CO2. Cells were
harvested and manually counted using a haemocytometer on alternate days from day 1 to
day 9 (A). Growth rate was determined relative to day 1 cell count. Nodal overexpression did not signficantly affect rate of growth. The doubling times for BeWo and
Nodal over-expressing cells were 24.5 and 20.3 hours, respectively (P=0.101). Cells were
also plated at 2 x 103 cells/well of 96-well plates in complete DMEM. Cells were
incubated at 37°C, 5% CO2 for 24 hours. BrdU labeling solution was added to the culture
medium and cells were further incubated for 24 hours. Cells were fixed with 100 ul/well
fix solution for 30 min at room temperature and incubated with anti-BrdU antibody
conjugate with peroxidase for 90 min. A substrate soltion was then added into each well,
and absorbance was measured (B). Neither Nodal over-expression or treatment with
10uM Nodal/Activin inhibitor, SB431542, had a significant affect on BeWo proliferation.
BrdU proliferation data are represented as a median ± interquartile range (IQR) for five
independent experiments with each condition measured 8 times. Different characters
indicate significant differences (p<0.05).
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Nodal differentially regulates proliferation & apoptosis in HTR-8/SVneo and BeWo cells.
Given the results observed between the growth curves and proliferation of HTR8/SVneo cells, we decided to do a viability/cytotoxicity assay to determine the ratio of
metabolically active cells to apoptotic cells. Using the LIVE/DEAD assay, Nodal knockdown in HTR-8/SVneo cells was found to significantly decrease the number of
metabolically active cells starting at day 3 (Figure 15-A), while increasing the number of
apoptotic cells between days 3 to 5 (Figure 15-B). Of note, there was no difference at day
1 when BrdU assays were conducted. When the cells were at high confluence (days 7 and
9) apoptosis was approximately equal between the control and Nodal knock-down cells.
Contrary to the above results, Nodal over-expression in BeWo cells also led to a
significant decrease in the number of metabolically active cells starting at day 7 (Figure
16-A), while increasing the number of apoptotic cells on the same day (Figure 16-B).
However, at day 1 there was no effect on proliferation, which confirms our BrdU results.
Nodal expression does not affect secreted hCG protein
To determine the effect of Nodal on the ability of HTR-8/SVneo cells to
differentiate along the villous pathway, cells were treated with Forskolin (an inducer of
syncytialization and hCG production) and RNA and conditioned medium were collected.
qRT-PCR and ELISA were conducted for human chorionic gonadotropin (hCG).
Regarding hCG mRNA expression, basal and induced expression was greatest after
Nodal knock-down in HTR-8/SVneo cells (Figure 17-A). However, secreted hCG was
not detected in either shSCR nor shNodal even after treatment with Forskolin (Figure 17B). In BeWo cells, Nodal over-expression did not alter basal or induced secretion of hCG
(Figure 18-A,B).
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Figure 15. Nodal knock-down decreases the ratio of metabolically active to apoptotic
cells in HTR-8/SVneo.
HTR-8/SVneo scrambled control (shSCR) and shRNANodal knock-down (shNodal) cells
were plated at 3.25 x 102 cells/well in 96-well plates (n=8). Cells were incubated at 37°C,
5% and analyzed using the LIVE/DEAD assay on alternate days from day 1 to day 9.
Briefly, dead control wells were treated with DMSO and incubated for 15 min. Live
control wells were washed 3X with DPBS. Wells were then labeled with 100 µl/well of
appropriate dye solution and incubated for 45 min at room temperature in the dark.
Fluorescence was then measured using a microplate reader. Nodal knock-down
moderately decreased the percentage of metabolically active cells (A) and slightly
increased the percentage of apoptotic cells (B). LIVE/DEAD data are represented as
median ± interquartile range (IQR) with n=8. Experiment was completed three
independent times with similar results. (*) indicates significant differences (p<0.05).
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Figure 16. Nodal over-expression decreases the ratio of metabolically active cells to
apoptotic cells in BeWo.
BeWo parental (BeWo) and Nodal over-expressing (NOE) cells were plated at 3.25 x 102
cells/well in 96-well plates (n=8). Cells were incubated at 37°C, 5% and analyzed using
the LIVE/DEAD assay on alternate days from day 1 to day 9. Briefly, dead control wells
were treated with DMSO and incubated for 15 min. Live control wells were washed 3X
with DPBS. Wells were then labeled with 100 µl/well of appropriate dye solution and
incubated for 45 min at room temperature in the dark. Fluorescence was then measured
using a microplate reader. Nodal over-expression decreased the percentage of
metabolically active cells (A) however had no significant effect on the percentage of
apoptotic cells (B). LIVE/DEAD data are represented as median ± interquartile range
(IQR) with n=8. Experiment was completed three independent times with similar results.
(*) indicates significant differences (p<0.05).
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Figure 17. Nodal knock-down increases hCG mRNA but not secreted protein in
HTR-8/SVneo cells.
HTR-8/SVneo scrambled control (shSCR) and shRNANodal knock-down (shNodal) cells
were plated in 6-well plates in complete F-12K medium with or without 50 uM Forskolin
and incubated at 37°C, 5% CO2 for 48 hours. Conditioned medium was collected and
RNA was extracted. qRT-PCR was used to quantify human chorionic gonadotropin
(hCG) mRNA (A). hCG mRNA expression increased with Nodal knock-down. ELISA
was used to quantify secreted hCG protein (B). Secreted hCG was not detected in either
shSCR or shNodal cells. Data are represented as a median ± interquartile range (IQR) for
three independent experiments with each condition being tested in triplicate. Different
characters indicate significant differences (p<0.05).
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Figure 18. Nodal over-expression does not affect hCG expression in BeWo cells.
BeWo parental (BeWo) and Nodal over-expressing (NOE) cells were plated in 6-well
plates in complete F-12K medium with or without 50 uM Forskolin and incubated at
37°C, 5% CO2 for 48 hours. Conditioned medium was collected and RNA was extracted.
qRT-PCR was used to quantify human chorionic gonadotropin (hCG) mRNA (A).
Foskolin treatment did not significantly increase hCG mRNA in either cell type. ELISA
was used to quantify secreted hCG protein. Forskolin treatment did increase hCG
secretion in both BeWo and NOE, however basal and induced amounts were equivalent
between the two cell lines. Data are represented as a median ± interquartile range (IQR)
for three independent experiments with each condition being tested in triplicate. Different
characters indicate significant differences (p<0.05).
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Forskolin treatment increased hCG mRNA expression as well as secreted protein
comparably between parental and Nodal over-expressing cells (Figure 18-A,B).
Nodal expression is required for endothelial-like tube formation capacity.
To determine the effect of Nodal on the ability of HTR-8/SVneo cells to
differentiate along the extravillous (endovascular) pathway, a vascular-like tubeformation assay was performed along with qRT-PCR for VE-Cadherin mRNA. Nodal
knock-down significantly decreased the ability of HTR-8/SVneo cells to form tubes on
Matrigel (Figure 19-A,B). Nodal knock-down also decreased the expression of VECadherin mRNA relative to HTR-8/SVneo scrambled controls (Figure 19-C). In
agreement with what was observed in the Nodal knock-down HTR-8/SVneo cells, Nodal
over-expression in BeWo led to increased tube formation capacity relative to parental
control cells (Figure 20-A,B). VE-Cadherin expression, however, did not increase in
BeWo Nodal over-expressing cells compared to BeWo parental cells (Figure 20-C).
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Figure 19. Nodal is required for HTR-8/SVneo tube-formation and VE-Cadherin
expression.
HTR-8/SVneo scrambled control (shSCR) and shRNANodal knock-down (shNodal) cells
were seeded on 12-well plates coated with a thin layer of diluted growth factor reduced
(GFR) MatrigelTM in serum-free medium. Cells were incubated at 37°C, 5% CO2.
Pictures were taken after 18 hours of incubation (A). Scale bar represents 100 µm. Tube
formation decreased with Nodal knock-down. The extent of tube formation was measured
by quantifying the number of branch points using ImageJ software (B). RNA was
extracted from HTR-8/SVneo shSCR and shNodal cells. cDNA was synthesized and
qRT-PCR was used to quantify VE-Cadherin mRNA (C). VE-Cadherin expression
decreased with Nodal knock-down. Data are represented as a median ± interquartile
range (IQR) for three independent experiments with each condition being tested in
triplicate. Different characters indicate significant differences (p<0.05).
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Figure 20. Nodal over-expression increases BeWo tube-formation.
BeWo parental (BeWo) and Nodal over-expressing (NOE) cells were seeded on 12-well
plates coated with a thin layer of diluted growth factor reduced (GFR) MatrigelTM in
serum-free medium. Cells were incubated at 37°C, 5% CO2. Pictures were taken after 18
hours of incubation (A). Scale bar represents 100 µm. Tube formation increased with
Nodal over-expression. The extent of tube formation was measured by quantifying the
number of branch points using ImageJ software (B). RNA was extracted from BeWo and
NOE cells. cDNA was synthesized and qRT-PCR was used to quantify VE-Cadherin
mRNA (C). VE-Cadherin expression did not increase with Nodal over-expression. Data
are represented as a median ± interquartile range (IQR) for three independent
experiments with each condition being tested in triplicate. Different characters indicate
significant differences (p<0.05).
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The placenta is an organ required by Eutherian mammals for the successful
development of the fetus during pregnancy (reviewed by (Herr et al., 2010)). The human
placenta develops from highly proliferative and phenotypically plastic cells called
trophoblasts, which are derived from the trophectoderm of the pre-implantation
blastocyst (Lala & Hamilton, 1996). Cytotrophoblast stem cells, which adhere to the
basement membrane of chorionic villi via the integrin α6β4, self-renew and differentiate
along the villous and extravillous pathways to form the specific tissues of the placenta
(Huppertz, 2008). When the mechanisms regulating this self-renewal and differentiation
are disrupted, various placental disorders can occur, including impaired implantation and
preeclampsia. Due to a lack of suitable cytotrophoblast models, the factors responsible
for regulating these processes have not been fully elucidated.
Recent work in our lab has shown that a subpopulation of HTR-8/SVneo cells
expresses α6β4 integrin and that an α6β4high subset can be isolated using FACS (Zhong
et al., 2008). This subset exhibits significantly higher colony forming capacity, a
measure of self-renewal, as well as enhanced ability to differentiate along the villous
pathway, as indicated by increased hCG expression, as well as the extravillous pathway,
illustrated by enhanced invasion, VE-Cadherin expression, and endothelial-like tube
formation (Zhong et al., 2008).
The present study aimed to further characterize this α6β4high cytotrophoblast
progenitor subpopulation in the HTR-8/SVneo cell line, as well as to determine the role
of Nodal on trophoblast self-renewal, proliferation, and differentiation capacity. Utilizing
FACS and Western blot analysis, I discovered that the α6β4high subset expresses higher
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levels of Nodal protein, relative to the α6β4low subset. Subsequently, I examined loss and
gain of functions of Nodal and determined that Nodal maintains high levels of α6β4 and
is required for trophoblast self-renewal and differentiation along the extravillous
pathway, however does not appear to affect differentiation along the villous pathway.
While the current findings lend support for my hypothesis, further work will be required
to determine if these cells are indeed bi-potential with the capacity to differentiate along
the villous pathway in addition to the extravillous pathway.
4.1 HTR-8/SVneo & BeWo: Models for Trophoblast Self-Renewal & Differentiation
Studies examining the biology of trophoblasts have traditionally utilized primary
trophoblast cultures produced from the enzymatic dispersion of placental tissue (Kliman
et al., 1986) or short-lived primary cell lines generated from explants of first trimester
chorionic villi (Graham et al., 1992; Irving et al., 1995). The use of such cultures,
however, is often not suitable for certain studies due to their limited lifespan and inherent
heterogeneity in enzyme-dispersed cells (Graham et al., 1993). Primary cell lines
produced by the explant method live for around 3-4 passages, 12-15 passages in the case
of the HTR-8 line (Irving et al., 1995). As a result, trophoblast cell lines generated from
normal, immortalized cells or malignant trophoblast (choriocarcinoma) cells have been
used to study trophoblast biology and placental development (King et al., 2000).
This study employed the immortalized human trophoblast cell line, HTR8/SVneo, which is widely used to study trophoblast biology. These cells were
immortalized by introducing the simian virus 40 (SV40) large T antigen into the shortlived first trimester EVT cell line, HTR-8 (Graham et al., 1993). The parental HTR-8 was
generated by propagation of EVT cells migrating out of first trimester chorionic villus
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explants. The immortalized HTR-8/SVneo cells are morphologically similar to parental
(HTR-8) cells, exhibiting an epithelial phenotype, as well as cytokeratin 7 and hCG
expression. They also retained the ability to be regulated by TGF-β, a function that is
often lost in malignant choriocarcinoma cells (Graham et al., 1993). Expression of class 1
MHC subclass HLA-G is a well-known marker for the EVT lineage. The HLA-G gene
had previously been cloned from HTR-8 cells (Zdravkovic et al., 1999). HTR-8 and
HTR-8/SVneo cells at earlier passages were previously shown to express HLA-G
(Zdravkovic et al., 1999; Kalkunte et al., 2008; Khanet et al., 2010). The HTR-8/SVneo
cells used in the current study appear to have lost HLA-G expression (Appendix, Figure
A4). These results are similar to the findings of the loss of HLA-G expression by tumour
cells in culture in the case of melanoma (Rouas-Freiss et al., 2005), ovarian carcinoma
(Malmberg et al., 2002), renal cell carcinoma (Bukur et al., 2003) and gastric cancer (Ye
et al., 2009) cells. The down-regulation observed in gastric cancer has been attributed to
hypermethylation of the HLA-G gene promoter (Ye et al., 2009). Thus, a similar
mechanism may have mediated the silencing of HLA-G in the presently used HTR8/SVneo cells.
The choriocarcinoma cell line, BeWo, was selected for the Nodal over-expression
studies as these cells express low basal levels of Nodal protein and exhibit a more
differentiated phenotype, making them a suitable model for examining whether enhanced
Nodal expression can revert cells toward a less differentiated, progenitor cell type. This
cell line was established from a trophoblastic tumour of the placenta and produces
progesterone, hCG, and placental lactogen in culture. While choriocarcinoma cell lines
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have been used extensively to study trophoblast biology, in certain circumstances they
may behave differently from normal trophoblasts due to their malignant phenotype.
4.2 Nodal Signaling & Cytotrophoblast Progenitors
The strict regulation of cytotrophoblast progenitor self-renewal and differentiation
is a critical component in the establishment of successful pregnancy. Our results suggest
that Nodal may play a key role in this process, as Nodal protein level was found to be
elevated in our cytotrophoblast progenitor model, the α6β4high subpopulation in HTR8/SVneo, relative to the α6β4low subpopulation. Accordingly, Nodal and members of the
Nodal signaling pathway have been associated with various stem and progenitor cell
types, including human embryonic and mouse epiblast stem cells, mammary gland
progenitors, cancer stem-cell phenotypes (e.g. breast and prostate), as well as trophoblast
stem cells (Vallier et al., 2009; Strizzi et al., 2008; Meyer et al., 2009; Lonardo et al.,
2011; Guzman-Ayala et al., 2004). The Fisher group (2011) recently implicated the
importance of Nodal signaling in the maintenance of trophoblast stem cells. They found
that the Nodal/Activin inhibitor, SB431542 was required to derive trophoblast
progenitors able to differentiate along the villous and extravillous pathways, suggesting
that Nodal may function to maintain a more undifferentiated trophoblast stem cell
(Genbacev et al., 2011). It is possible that our α6β4high subpopulation encompasses this
more undifferentiated trophoblast stem cell population; however further studies will be
required to demonstrate this. These studies may include examining the expression of
trophoblast stem cell associated transcription factors, including ELF5, Cdx2, and Eomes
to determine how stem-like this population is. Additionally, the epigenetic signature of
this subpopulation may be examined to determine whether or not the specific epigenetic
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marks characteristic of trophoblast stem cells are retained (Dahle et al., 2010). In the
current study, we attempted to determine if the miRNA expression profile of this
subpopulation differed from that of the α6β4low subpopulation using a combined
miRNA/exon array, and whether these changes were characteristic of more stem-like
trophoblasts (Appendix, Table A2). While differences were observed between the two
populations, none of our increased miRNA were cited in the literature as being associated
with trophoblast stem cells. These results will hopefully help direct future studies into the
specific miRNA expression pattern of trophoblast stem/progenitor cells.
In addition to enhanced Nodal expression in our α6β4high cytotrophoblast
subpopulation, we also found that in both HTR-8/SVneo and BeWo cells, Nodal
increases expression of the integrin α6 and β4 subunit chains resulting in an apparent
increase in the percentage of α6β4high cells. While this is an indirect measurement
utilizing integrin subunits, heterodimer surface expression can be inferred from such
studies as (1) individual α or β subunits are not transported to the cell surface (Springer
et al., 1987; Heino et al., 1989), (2) α6 and β4 co-localization has been confirmed using
immunocytochemistry in HTR-8/SVneo, and (3) while α6 may form heterodimers with
β1 and β4, immunoprecipitation studies show that α6 preferentially associates with β4
rather than β1 (Hemler et al., 1989).
While α6β4 may function as an adhesion molecule on the basal surface of the
cytotrophoblast progenitor population for laminin-5 molecules on the basement
membrane in situ, this integrin may also maintain the self-renewal capacity of the
progenitors. Increased clonogenicity of α6β4high trophoblast cells even in the absence of
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laminin coating of the wells in our study supports the second possibility. This is
consistent with recent reports in other tissues. For example, a stem cell associated
function has been ascribed to α6β4 for a small subset of progenitor cells in the adult lung
alveolar epithelium, capable of self-renewal and differentiation into mature cell types in
vitro and in vivo (Chapman et al., 2011). Furthermore, α6 has been reported to be
associated with stem cell functions in mesenchymal (Lee et al., 2009; Yu et al., 2012),
mammary epithelial (Stingl et al., 2006), and hematopoietic stem cells (Qian et al., 2006).
In the case of mesenchymal stem cells, this has been shown to be via SOX2 and OCT4
(Yu et al., 2012). These studies combined with our results suggest that Nodal may
mediate the maintenance of cytotrophoblast stem cells, at least in part through the
expression of integrin α6β4.
Proper regulation of integrin α6β4 expression is important for implantation and
normal placental development. During implantation, trophoblasts modulate their integrin
expression profile to bind specific laminins and fibronectins expressed in the decidua and
thereby derive the traction required for migration. Zhou et al. (1993) have shown that
regulation of integrin expression is deregulated in preeclamptic placentae, which exhibit
limited trophoblast invasion. They found that invasive extravillous trophoblast cells fail
to down-regulate integrin α6β4, which characterizes non-migratory, epithelial cells,
including villous cytotrophoblast and is not associated with an invasive phenotype (Zhou
et al., 1993). Additionally, these cells fail to up-regulate integrin α1β1, a fibronectin
receptor normally associated with invasive EVT cells. Thus, this altered integrin
expression pattern in preeclamptic trophoblast may underlie the impaired trophoblast
invasion associated with this syndrome. By extension, deregulated Nodal signaling may
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be contributing to this altered integrin expression profile. Further studies into the
regulation of trophoblast integrin expression by Nodal may thus prove important for
discovering therapeutic treatments for this disease.
4.3 Nodal & Trophoblast Self-Renewal/Proliferation
An important hallmark of cytotrophoblast progenitors is the ability to self-renew
and proliferate. We found that Nodal appears to regulator self-renewal in both HTR8/SVneo and BeWo cells. In the mouse, Nodal signaling in the epiblast has been shown
to sustain Oct4 and Fgf4 transcription, thereby maintaining trophoblast stem cell selfrenewal in the adjacent extraembryonic ectoderm (Guzman-Ayala et al., 2004). In
contrast, Nodal appears to differentially regulate growth and proliferation in HTR8/SVneo and BeWo cell lines. In the former, Nodal knock-down decreased the rate of
growth while minimally increasing proliferation. This discrepancy was explained by an
increase in apoptosis in the Nodal knock-down cells. Thus, while Nodal decreased
proliferation, it simultaneously decreased apoptosis resulting in an overall elevated
metabolically active to apoptotic cell ratio in HTR-8/SVneo. These results support our
hypothesis that Nodal maintains a proliferative cytotrophoblast progenitor population.
These findings are also in accordance with previous reports that TGF-‐β/Activin signaling
maintains	
  proliferation of mouse trophoblast stem cells (Erlebacher et al., 2004). This
study, using the mouse trophoblast cell line, TSInk4a, demonstrated that TGF-‐β	
  or
Activin	
  in the presence of FGF4 is necessary and sufficient to maintain trophoblast stem
cell proliferation as measured by manual counting over 9 days. In an apparent paradox,
TGF-β normally inhibits cell-cycle-progression in nontransformed epithelial cells, by
regulating the transcription of cell-cycle regulators, including downregulation of c-Myc, a
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ubiquitous transcription factor critical for cell-cycle progression, and Id family members,
which promote cell cycle progression and inhibit cell differentiation via basic helix-loophelix transcription factors (Chen et al., 2002; Kang et al., 2003). As such, Erlebacher and
colleagues (2004) went on to show that FGF4 signaling prevents TGF-β induced downregulation of c-Myc, thereby elucidating a mechanism by which TGF-‐β	
  can act as a
growth promoter rather than inhibitor in trophoblast stem cells. It is thus possible that
Nodal is acting in concert with other factors to maintain trophoblast proliferation in HTR8/SVneo.
	
  

Conversely, we discovered that Nodal did not significantly alter growth rate or

proliferation in BeWo cells, however at high confluence and stress, Nodal overexpression decreased the number of metabolically active cells while increasing the
number of apoptotic cells. One potential explanation for the discrepancy in Nodal
function between HTR-8/SVneo and BeWo is the malignant nature of the BeWo cell line.
It has previously been demonstrated that TGF-‐β	
  signaling can become deregulated in
choriocarcinoma cells. Graham et al. (1994) showed that while TGF-β inhibited
proliferation and invasion in the normal HTR-8/SVneo trophoblast cells, the
choriocarcinoma cell lines, JAR and JEG-3 were unresponsive to TGF-β (Graham et al.,
1994). It has been suggested that a potential mechanism by which tumorigenic cells
escape TGF-β induced growth arrest is via mutation of Smads, or the acquisition of
oncogenic proteins capable of inhibiting Smad function (Massague et al., 2000; Derynck
et al., 2001). For example, Smad3 expression was found to be lost in JAR and JEG-3
choriocarcinoma cells and generation of a Smad3-restituted JAR cell line partially
restored its response to TGF-β (Xu et al., 2003). BeWo cells, however, have been shown
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to express both Smad2 and Smad3 mRNA (Munir et al., 2004). Thus, while it is possible
that tumorigenic transformation has rendered BeWo cells resistant to Nodal-induced
proliferation, the mechanism is unlikely to be due entirely to defects at the level of the
receptor or Smad signaling pathway, as Nodal is functional in regulating clonogenicity
and tube-formation in these cells. Further studies will be required to elucidate the
mechanisms underlying the resistance of BeWo cells to Nodal-induced growth.
A study by Munir et al. (2004) stated that Nodal inhibits proliferation and
stimulates apoptosis in trophoblast cells. While these results contradict our findings in
HTR-8/SVneo, the majority of their work was conducted on the choriocarcinoma cell
line, JEG-3. Accordingly, their results more closely reflect those observed here in BeWo
cells. Additionally, while they show that Nodal or constitutively active ALK7 (caALK7)
decreases the number of metabolically active HTR-8/SVneo cells in an MTT assay, they
failed to examine simultaneous rates of apoptosis. They instead examined expression of
p27, Cdk2, cyclin E and cyclin D1 by Western blot. Their data show that in both JEG-3
and HTR-3/SVneo cells, both Nodal and caALK7 increased expression of p27 and
decreased expression of cyclin D1 and Cdk2, (Munir et al, 2004). While these results
suggest impaired cell cycle progression, they do not measure overall cell growth, which
may explain the discrepancy as our results show that while Nodal decreases proliferation
in HTR-8/SVneo cells, it simultaneously decreases apoptosis, resulting in an overall
stimulatory effect on growth.
Alternatively, these differences may be a result of concentration dependent effects
of Nodal. The study by Munir over-expressed Nodal in cells that express high
endogenous levels of Nodal, while here we knock-down Nodal in cells that express high
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endogenous Nodal and over-expressed Nodal in cells that express low endogenous Nodal.
Therefore, these studies may be highlighting a potential concentration-dependent
signaling mechanism. Work by other members of our lab showed that treatment of T47D
and MCF-7 breast cancer cells or HTR-8/SVneo trophoblast cells with 0, 50, 100 or 500
ng/ml of rhNodal resulted in bi-phasic migration response, with low levels of rhNodal
stimulating migration while higher levels reduced migration to basal levels (Quail et al.,
2011; Law et al, 2011). Such concentration dependent effects of Nodal signaling are also
seen in zebrafish and mouse development, where different levels of Nodal signaling
induce different genes and thus cell fates; for example, in the mouse, high levels of Nodal
signaling are thought to be required for node and anterior mesendoderm formation, while
lower levels induce formation of posterior mesoderm (Lowe et al., 2001). Further work is
needed to clarify exactly how Nodal signaling affects trophoblast self-renewal and
proliferation, and whether concentration-dependent affects are involved.
4.4 Nodal & Trophoblast Differentiation
Currently, the full complement of factors responsible for maintaining the
multipotent state as well as directing the differentiation of human cytotrophoblast
progenitor cells remains unknown. Our results suggest that Nodal may be an important
factor that allows trophoblasts to respond to microenvironmental cues directing
differentiation. We show that Nodal is critical for enabling both HTR-8/SVneo and
BeWo cells to adopt an endothelial-like tube morphology in response to the matrix
components provided by Matrigel. This is reminiscent of the epithelial-to-endothelial
transition that occurs as cytotrophoblast cells invade and remodel spiral arteries along the
extravillous pathway. Accordingly, it is well established that Nodal maintains
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pluripotency in human embryonic stem cells and mouse epiblast stem cells via
upregulation of the key pluripotency factor, Nanog (Vallier et al., 2009). Thus, Nodal
may similarly upregulate key multipotency factors in trophoblast stem cells. Additionally,
work in the mouse suggests that Nodal also directs trophoblast differentiation (Ma et al.,
2001). Work with Nodal null mutants revealed complete loss of spongiotrophoblast and
labyrinth layers concomitant with expansion of the giant cell layer. Conversely,
decreased Nodal signaling in a hypomorphic mutant led to expansion of the giant cell and
spongiotrophoblast layers (Ma et al., 2001). Furthermore, expression of Nodal in the rat
choriocarcinoma cell line, Rcho-1 was found to inhibit trophoblast giant cell
differentiation (Ma et al., 2001). Taken together, these findings suggest that in the mouse,
Nodal directs trophoblast fate towards the labyrinth lineage (homologous to the human
syncytiotrophoblast), while maintaining the thin layers of giant cells and
spongiotrophoblast (the human cytotrophoblast homologue) (Ma et al., 2001).
It has recently been suggested that dose-dependent Nodal signaling strictly
balances mouse trophoblast self-renewal and differentiation in conjunction with the
alleged Smad4 inhibitor, ectodermin (Ecto or TRIM33) (Morsut et al., 2010). Utilizing
Ecto-/- mutants, Morsut and colleagues (2010) demonstrate that “unrestrained”
Nodal/Smad4 signaling leads to trophoblast differentiation (indicated by upregulation of
4311 and GCM1) and depletion of the trophoblast stem cell compartment (indicated by
loss of Eomes, Cdk2, and Bmp4). These authors concluded that Nodal signaling
functions to stimulate trophoblast differentiation, while Ecto inhibits this to promote selfrenewal, thus governing the expansion and differentiation of trophoblast progenitors
(Morsut et al., 2010). While this study provides a nice mechanism for the dose regulation
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of Nodal signaling, the purported role of Ecto as a Nodal/Smad4 inhibitor remains
controversial. A recent paper by Xi et al. (2011) demonstrates that Ecto (here TRIM33)
actually mediates Nodal-induced activation of master regulators of differentiation in
hESCs. They show that in response to Nodal signaling, TRIM33 acts as a binding partner
for Smad2/3 and that this complex binds the poised histone mark, H3K9me3 in the
promoters of mesendoderm regulators, Gsc and Mixl1, freeing Nodal responsive
elements to enable Nodal-induced differentiation (Xi et al., 2011). It is feasible therefore
that TRIM33 (or Ecto) may instead function as an enhancer of Nodal signaling for
specific downstream targets, rather than an inhibitor of Nodal signaling and
differentiation in trophoblast stem cells.
The above studies appear to contradict the work of Guzman-Ayala et al (2004)
and the current study suggesting that Nodal signaling maintains trophoblast stem cell
self-renewal. A potential explanation for this discrepancy can be derived from the dual
role of Nodal signaling observed in hESCs, where Nodal signaling maintains
pluripotency through expression of the transcription factor Nanog, however in
conjunction with BMP4 induces differentiation into mesendoderm and subsequently
endoderm (Vallier et al., 2009). It is thus possible that Nodal may maintain trophoblast
stem cell self-renewal via upregulation of FGF4, however in conjunction with
Ecto/TRIM33, Nodal may convert into an inductive signal for differentiation. Future
studies will be required to untangle the full complement of Nodal downstream targets as
well as potential co-activators and co–repressors mediating self-renewal and
differentiation in trophoblast stem cells.
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While our results suggest Nodal is required to enable trophoblasts to differentiate
along the extravillous pathway, we did not see an effect in differentiation along the
villous pathway. This may be due to our use of the single syncytiotrophoblast marker,
hCG. That hCG may not be an adequate marker of syncytiotrophoblast differentiation is
indicated by a study demonstrating a dissociation between morphological and
biochemical differentiation in JEG-3 cells (Al-Nasiry et al., 2006). These authors found
that treatment with Forskolin led to increased secretion of hCG, however did not induce
syncytial fusion as indicated by E-cadherin staining. Conversely, Nodal may be acting to
direct trophoblast fate towards the extravillous trophoblast lineage. Future studies should
employ more markers of syncytiotrophoblast, including the fusogenic protein, Syncytin.
4.5 Experimental Limitations
The proposed conclusions in this study rely on results obtained from an in vitro
model using the immortalized extravillous trophoblast cell line, HTR-8/SVneo and the
malignant choriocarcinoma cell line, BeWo. Despite the widespread use of these cell
lines for the examination of trophoblast functions in in vitro assays, such as cell
migration and syncytial fusion, they do not describe the full situation in situ. This study
provides an initial overview of the possible mechanism by which Nodal affects
trophoblast self-renewal, proliferation, and differentiation along the villous and
extravillous pathways.
In this study we used individual antibodies to the α6 and β4 integrin subunits as a
marker for cytotrophoblasts. This is an indirect measurement of the integrin α6β4 and
results should be taken at face value. In the future, a greater number of cytotrophoblast
makers should be utilized, such as Eomes, Cdk2, and ELF5. Additionally, as mentioned
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above, a greater number of markers for syncytiotrophoblast differentiation should be
used, such as Syncytin, as well as a functional assay, such as syncytial fusion. While the
limiting dilution clonogenic assay is a good initial test for self-renewal, the true test must
include dissociation of the resulting colony and re-plating of individual cells to prove that
the clonal cells retained the ability to self-renew over multiple passages. Finally, the
majority of experiments presented here were completed with an n = 3. To strengthen the
results, a greater number of replicates should be completed.
4.6 Future Directions
Notwithstanding these potential limitations, the work done in the current study
provides novel insights into the mechanisms by which Nodal regulates trophoblast selfrenewal and differentiation. To gain greater confidence in our results, experiments should
be repeated in the primary trophoblast progenitor cell line recently produced by the
Fisher lab (Genbacev et al., 2011). Due to the complex nature of the Nodal signaling
cascade, future studies should aim to utilize a wide range of Nodal concentrations to
further elucidate the putative concentration-dependent dose response. Additionally,
future studies should aim to unravel the full complement of co-activators and corepressors, and how these mediate the effects of Nodal signaling in trophoblast stem cell
self-renewal and differentiation. Finally, given the growing number of studies supporting
a role for epigenetic regulation of Nodal signaling, further work should be completed to
determine how this affects downstream targets in the various trophoblast cell types.
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Figure A1. Analysis of α6β4 expression in HTR-8/SVneo cells.
Flow cytometry analysis of α6 (top) and β4 (bottom) integrin subunits in HTR-8/SVneo
cells (A). Confocal microscopy indicating colocalization of α6 (red) and β4 (green)
integrin subunits (B). White arrows indicate areas of colocalization. Scale bar represents
10 µm. Completed by Lynne Postovit.
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Figure A2. Isolation of α6β4high and α6β4low subsets from HTR-8/SVneo.
HTR-8/SVneo cells were harvested and incubated with IgG isotype controls, FITC
conjugated rat anti-human CD49f IgG (specific for α6 integrin chain) and/or PE
conjugated rat anti-human CD104 (specific for β4 integrin chain). Signals obtained with
isotype controls were gated as negative prior to analysis of integrin expression. Singlets
were gated according to FSC and SSC height and width signals. The top 20% of HTR8/SVneo cells were sorted as α6β4high while the bottom 20% were sorted as α6β4low.
Post sorting, the purity for the α6β4high subset was very high, with 1.2% of singlets
detected as negative. The α6β4low had 0.9% of singlets in the positive range.
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Figure A3. Characteriziation of α6β4high and α6β4low subsets from HTR-8/SVneo.
The integrin α6β4high subset exhibited greater clonogenicity (C) and differentiation along
the villous, exhibited by greater hCG expression (D), and extravillous pathway, exhibited
by enhanced invasion (E), VE-Cadherin expression (F) and tube formation capacity (G).
Scale bar represents 100 µM. (*) indicates significant differences (p<0.05) between
treatment and control. Completed by Charles Zhong and Lynne Postovit.
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Figure A4. Loss of HLA-G expression in HTR-8/SVneo.
Flow cytometry analysis of surface HLA-G expression in the cell line, HTR-8/SVneo
showing that these cells no longer express HLA-G. Conversely, 94.5% of the positive
control, JEG-3 cells express HLA-G.
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Table A1. Top 20 increased miRNA and corresponding decreased target genes in
α6β4high relative to α6β4low subset.
RNA was extracted from α6β4high and α6β4low subsets. Single stranded cDNA was
prepared, and 5.5 ug was end labeled and hybridized, for 16 hours at 45°C, to Human
Exon 1.0 ST arrays. One microgram of total RNA was labeled and hybridized to
Affymetrix miRNA 2.0 arrays for 16 hours at 45°C. Probe level (.CEL file) data was
generated and Probes were summarized to miRNA or gene level in Partek Genomics
Suite using the RMA algorithm. Partek was used to determine ANOVA p-values and
fold changes for genes and fold changes for miRNAs. Species annotations were added
and used to filter only those miRNAs found in Homo sapiens. The gene targets for
increased Homo sapiens miRNAs were determined using TargetScan v5.2 and correlated
with a minimum 1.5-fold, decreased genes.
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miRNA

Foldchange

Target
Gene

Foldchange

GO Biological Process
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4.8014
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Response to reactive oxygen
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Regulation of cell migration
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rRNA processing
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Cotranslational protein targeting
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